WO2004014382A1 - Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds - Google Patents
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds Download PDFInfo
- Publication number
- WO2004014382A1 WO2004014382A1 PCT/US2003/024087 US0324087W WO2004014382A1 WO 2004014382 A1 WO2004014382 A1 WO 2004014382A1 US 0324087 W US0324087 W US 0324087W WO 2004014382 A1 WO2004014382 A1 WO 2004014382A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- optionally substituted
- groups
- same
- different
- Prior art date
Links
- 0 CC(C*)N(*)c1nc(*)c(*)c(*)n1 Chemical compound CC(C*)N(*)c1nc(*)c(*)c(*)n1 0.000 description 7
- DYJPVSYLWLJPEE-UHFFFAOYSA-N CNC(COC)=O Chemical compound CNC(COC)=O DYJPVSYLWLJPEE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- the present invention relates generally to 2,4-pyrimidinediamine compounds, pharmaceutical compositions comprising the compounds, intermediates and synthetic methods of making the compounds and methods of using the compounds and compositions in a variety of contexts, such as in the treatment or prevention of autoimmune diseases and/or the symptoms associated therewith.
- Crosslinking of Fc receptors such as the high affinity receptor for IgE (FceRI) and/or the high affinity receptor for IgG (Fc ⁇ RI) activates a signaling cascade in mast, basophil and other immune cells that results in the release of chemical mediators responsible for numerous adverse events.
- Fc receptors such as the high affinity receptor for IgE (FceRI) and/or the high affinity receptor for IgG (Fc ⁇ RI) activates a signaling cascade in mast, basophil and other immune cells that results in the release of chemical mediators responsible for numerous adverse events.
- Fc receptors such as the high affinity receptor for IgE (FceRI) and/or the high affinity receptor for IgG (Fc ⁇ RI) activates a signaling cascade in mast, basophil and other immune cells that results in the release of chemical mediators responsible for numerous adverse events.
- Fc receptors such as the high affinity receptor for IgE (FceRI) and/or the high affinity receptor for IgG (Fc ⁇ RI) activates a
- the signaling cascade(s) activated by crosslinking Fc receptors such as FceRI and/or Fc ⁇ RI comprises an array of cellular proteins.
- Fc receptors such as FceRI and/or Fc ⁇ RI
- the signaling cascade(s) activated by crosslinking Fc receptors such as FceRI and/or Fc ⁇ RI comprises an array of cellular proteins.
- tyrosine kinases an important tyrosine kinase involved in the signal transduction pathways associated with crosslinking the FceRI and/or Fc ⁇ RI receptors, as well as other signal transduction cascades.
- Syk kinase see Valent et al., 2002, Intl. J. Hematol. 75(4):257-362 for review).
- the present invention provides novel 2,4-pyrimidinediamine compounds that, as will be discussed in more detail below, have myriad biological activities.
- the compounds generally comprise a 2,4-pyrimidinediamine "core" having the following structure and numbering convention:
- the compounds of the invention are substituted at the C2 nitrogen (N2) to form a secondary amine and are optionally further substituted at one or more of the following positions: the C4 nitrogen (N4), the C5 position and/or the C6 position.
- the substituent forms a secondary amine.
- the substituent at N2, as well as the optional substituents at the other positions, may range broadly in character and physico- chemical properties.
- the substituent(s) may be a branched, straight-chained or cyclic alkyl, a branched, straight-chained or cyclic heteroalkyl, a mono- or polycyclic aryl a mono- or polycyclic heteroaryl or combinations of these groups.
- These substituent groups may be further substituted, as will be described in more detail below.
- the N2 and or N4 substituents may be attached directly to their respective nitrogen atoms, or they may be spaced away from their respective nitrogen atoms via linkers, which may be the same or different.
- the nature of the linkers can vary widely, and can include virtually any combination of atoms or groups useful for spacing one molecular moiety from another.
- the linker may be an acyclic hydrocarbon bridge (e.g, a saturated or unsaturated alkyleno such as methano, ethano, etheno, propano, prop[l]eno, butano, but[l]eno, but[2]eno, buta[l,3]dieno, and the like), a monocyclic or polycyclic hydrocarbon bridge (e.g., [l,2]benzeno, [2,3]naphthaleno, and the like), a simple acyclic heteroatomic or heteroalkyldiyl bridge (e.g., -O-, -S-, -S-O-, -NH-, -PH-, -C(O)-, -C(O)NH-, -S(O)-, -S(O) 2 -, -S(O)NH-, -S(O) 2 NH-, -O-CH 2 -, -CH 2
- substituents at the N2, N4, C5 and or C6 positions, as well as the optional linkers, may be further substituted with one or more of the same or different substituent groups.
- the nature of these substituent groups may vary broadly.
- suitable substituent groups include branched, straight-chain or cyclic alkyls, mono- or polycyclic aryls, branched, straight-chain or cyclic heteroalkyls, mono- or polycyclic heteroaryls, halos, branched, straight-chain or cyclic haloalkyls, hydroxyls, oxos, thioxos, branched, straight-chain or cyclic alkoxys, branched, straight-chain or cyclic haloalkoxys, trifluoromethoxys, mono- or polycyclic aryloxys, mono- or polycyclic heteroaryloxys, ethers, alcohols, sulfides, thioethers, sulfanyls (thi
- the 2,4-pyrimidinediamine compounds of the invention are compounds according to structural formula (I):
- L 1 and L 2 are each, independently of one another, selected from the group consisting of a direct bond and a linker;
- R 2 is selected from the group consisting of (C1-C6) alkyl optionally substituted with one or more of the same or different R 8 groups, (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R 8 groups, cyclohexyl optionally substituted with one or more of the same or different R groups, 3-8 membered cycloheteroalkyl optionally substituted with one or more of the same or different R 8 groups, (C5-C15) aryl optionally substituted with one or more of the same or different R 8 groups, phenyl optionally substituted with one or more of the same or different R 8 groups and 5-15 membered heteroaryl optionally substituted with one or more of the same or different R 8 groups;
- R 4 is selected from the group consisting of hydrogen, (C1-C6) alkyl optionally substituted with one or
- R 5 is selected from the group consisting of R 6 , (C1-C6) alkyl optionally substituted with one or more of the same or different R 8 groups, (C1-C4) alkanyl optionally substituted with one or more of the same or different R 8 groups, (C2-C4) alkenyl optionally substituted with one or more of the same or different R 8 groups and (C2-C4) alkynyl optionally substituted with one or more of the same or different R 8 groups; each R 6 is independently selected from the group consisting of hydrogen, an electronegative group, -OR d , -SR d , (C1-C3) haloalkyloxy, (C1-C3) perhaloalkyloxy, -NR C R C , halogen, (C1-C3) haloalkyl, (C1-C3) perhaloalkyl, -CF 3 , -CH 2 CF 3 , -CF 2 CF 3 , -CN, -NC, -OC
- R 8 is selected from the group consisting of R a , R , R a substituted with one or more of the same or different R a or R , -OR a substituted with one or more of the same or different R a or R b , -B(OR a ) 2 , -B(NR C R C ) 2 , -(CH 2 ) resort r R b , -(CHR a ) admir r R , -O-(CH 2 ) m -R b , -S-(CH 2 ) m -R b , -O-CHR a R b , -O-CR a (R ) 2 , -O-(CHR a ) m -R b , -O- (CH 2 ) m -CH[(CH 2 ) m R b ]R b , -S-(CHR a ) w -R b ,
- each R a is independently selected from the group consisting of hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl
- the present invention provides prodrugs of the 2,4- pyrimidinediamine compounds.
- Such prodrugs may be active in their prodrug form, or may be inactive until converted under physiological or other conditions of use to an active drug form.
- one or more functional groups of the 2,4- pyrimidinediamine compounds are included in promoieties that cleave from the molecule under the conditions of use, typically by way of hydrolysis, enzymatic cleavage or some other cleavage mechanism, to yield the functional groups.
- promoieties that cleave from the molecule under the conditions of use, typically by way of hydrolysis, enzymatic cleavage or some other cleavage mechanism, to yield the functional groups.
- primary or secondary amino groups may be included in an amide promoiety that cleaves under conditions of use to generate the primary or secondary amino group.
- the prodrugs of the invention include special types of protecting groups, termed "progroups,” masking one or more functional groups of the 2,4-pyrimidinediamine compounds that cleave under the conditions of use to yield an active 2,4-pyrimidinediamine drug compound.
- Functional groups within the 2,4-pyrimidinediamine compounds that may be masked with progroups for inclusion in a promoiety include, but are not limited to, amines (primary and secondary), hydroxyls, sulfanyls (thiols), carboxyls, carbonyls, phenols, catechols, diols, alkynes, phosphates, etc.
- promoieties suitable for masking such functional groups to yield promoieties that are cleavable under the desired conditions of use are known in the art. All of these progroups, alone or in combinations, may be included in the prodrugs of the invention. Specific examples of promoieties that yield primary or secondary amine groups that can be included in the prodrugs of the invention include, but are not limited to amides, carbamates, imines, ureas, phosphenyls, phosphoryls and sulfenyls.
- promoieties that yield sulfanyl groups include, but are not limited to, thioethers, for example S-methyl derivatives (monothio, dithio, oxythio, aminothio acetals), silyl thioethers, thioesters, thiocarbonates, thiocarbamates, asymmetrical disulfides, etc.
- promoieties that cleave to yield hydroxyl groups that can be included in the prodrugs of the invention include, but are not limited to, sulfonates, esters and carbonates.
- promoieties that yield carboxyl groups that can be included in the prodrugs of the invention included, but are not limited to, esters (including silyl esters, oxamic acid esters and thioesters), amides and hydrazides.
- the prodrugs of the invention are compounds according to structural formula (I) in which the protecting group of R c and R d is a progroup. Replacing the hydrogens attached to N2 and N4 in the 2,4-pyrimidinediamines of structural formula (I) with substituents adversely affects the activity of the compounds.
- these nitrogens may be included in promoieties that, under conditions of use, cleave to yield 2,4-pyrimidinediamines according to structural formula (I).
- the prodrugs of the invention are compounds according to structural formula (II):
- R 2 , R 4 , R 5 , R 6 , L 1 and L 2 are as previously defined for structural formula (I); and R 2b and R 4b are each, independently of one another, a progroup.
- the present invention provides compositions comprising one or more compounds and/or prodrugs of the invention and an appropriate carrier, excipient or diluent.
- an appropriate carrier, excipient or diluent will depend upon the desired use for the composition, and may range from being suitable or acceptable for veterinary uses to being suitable or acceptable for human use.
- the present invention provides intermediates useful for synthesizing the 2,4-pyrimidinediamine compounds and prodrugs of the invention.
- the intermediates are 4-pyrimidineamines according to structural formula (III):
- R 4 , R 5 , R 6 and L 2 are as previously defined for structural formula (I); LG is a leaving group such as, for example, -S(O) 2 Me, -SMe or halo (e.g., F, Cl, Br, I); and R 4c is hydrogen or a progroup.
- the intermediates are 2-pyrimidineamines according to structural formula (IV): 004/014382
- LG is a leaving group, such as, for example, -S(O) 2 Me, -SMe or halo (e.g., F, Cl, Br, I) and R 2c is hydrogen or a progroup.
- the intermediates are 4-amino- or 4-hydroxy-2- pyrimidineamines according to structural formula (V):
- R 2 , R 5 , R 6 and L 1 are as previously defined for structural formula (I), R 7 is an amino or hydroxyl group and R 2c is hydrogen or a progroup.
- the intermediates are N4-substituted cytosines according to structural formula (VI):
- R 4 , R 5 , R 6 and L 2 are as previously defined for structural formula (I) and R 4c is hydrogen or a progroup.
- the present invention provides methods of synthesizing the 2,4-pyrimidinediamine compounds and prodrugs of the invention.
- the method involves reacting a 4-pyrimidineamine according to structural formula (III) with an amine of the formula HR M-L -R , where L , R and R are as previously defined for structural formula (IV) to yield a 2,4-pyrimidinediamine according to structural formula (I) or a prodrug according to structural formula (II).
- the method involves reacting a 2-pyrimidineamine according to structural formula (TV) with an amine of the formula R 4 -L 2 -NHR 4c where L 4 , R 4 and R 4c are as previously defined for structural formula (III) to yield a 2,4- pyrimidinediamine according to structural formula (I) or a prodrug according to structural formula (II).
- a 2-pyrimidineamine according to structural formula (TV) with an amine of the formula R 4 -L 2 -NHR 4c where L 4 , R 4 and R 4c are as previously defined for structural formula (III) to yield a 2,4- pyrimidinediamine according to structural formula (I) or a prodrug according to structural formula (II).
- the method involves reacting a 4-amino-2- pyrimidineamine according to structural formula (V) (in which R 7 is an amino group) with an amine of the formula R 4 -L 2 -NHR 4c , where L 2 , R 4 and R 4c are as defined for structural formula (III), to yield a 2,4-pyrimidinediamine according to structural formula (I) or a prodrug according to structural formula (II).
- the 4-ammo-2-pyrimidineamine may be reacted with a compound of the formula R 4 -L 2 -LG, where R 4 and L 2 are as previously defined for structural formula (I) and LG is a leaving group.
- the method involves halogenating a 4-hydroxy-2- pyrimidineamine according to structural formula (V) (R 7 is a hydroxyl group) to yield a 2- pyrimidineamine according to structural formula (IV) and reacting this pyrimidineamine with an appropriate amine, as described above.
- the method involves halogenating an N4-substituted cytosine according to structural formula (VI) to yield a 4-pyrimidineamine according to structural formula (III) and reacting this pyrimidineamine with an appropriate amine, as described above.
- the 2,4-pyrimidinediamine compounds of the invention are potent inhibitors of degranulation of immune cells, such as mast, basophil, neutrophil and/or eosinophil cells.
- the present invention provides methods of regulating, and in particular inhibiting, degranulation of such cells.
- the method generally involves contacting a cell that degranulates with an amount of a 2,4-pyrimidinediamine compound or prodrug of the invention, or an acceptable salt, hydrate, solvate, N-oxide and/or composition thereof, effective to regulate or inhibit degranulation of the cell.
- the method may be practiced in in vitro contexts or in in vivo contexts as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by or associated with cellular degranulation.
- biochemical data confirm that the 2,4-pyrimidinediamine compounds exert their degranulation inhibitory effect, at least in part, by blocking or inhibiting the signal transduction cascade(s) initiated by crosslinking of the high affinity Fc receptors for IgE ("FceRI”) and/or IgG (“Fc ⁇ RI”).
- FceRI high affinity Fc receptors for IgE
- Fc ⁇ RI IgG
- the 2,4-pyrimidinediamine compounds are potent inhibitors of both FceRI-mediated and Fc ⁇ RI-mediated degranulation.
- the 2,4-pyrimidine compounds may be used to inhibit these Fc receptor signalling cascades in any cell type expressing such FceRI and/or Fc ⁇ RI receptors including but not limited to macrophages, mast, basophil, neutrophil and/or eosinophil cells.
- the methods also permit the regulation of, and in particular the inhibition of, downstream processes that result as a consequence of activating such Fc receptor signaling cascade(s).
- downstream processes include, but are not limited to, FceRI-mediated and/or Fc ⁇ RI-mediated degranulation, cytokine production and/or the production and/or release of lipid mediators such as leukotrienes and prostaglandins.
- the method generally involves contacting a cell expressing an Fc receptor, such as one of the cell types discussed above, with an amount of a 2,4-pyrimidinediamine compound or prodrug of the invention, or an acceptable salt, hydrate, solvent, N-oxide and/or composition thereof, effective to regulate or inhibit the Fc receptor signaling cascade and/or a downstream process effected by the activation of this signaling cascade.
- an Fc receptor such as one of the cell types discussed above
- the method may be practiced in in vitro contexts or in in vivo contexts as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by or associated with the Fc receptor signaling cascade, such as diseases effected by the release of granule specific chemical mediators upon degranulation, the release and/or synthesis of cytokines and/or the release and/or synthesis of lipid mediators such as leukotrienes and prostaglandins.
- diseases characterized by, caused by or associated with the Fc receptor signaling cascade such as diseases effected by the release of granule specific chemical mediators upon degranulation, the release and/or synthesis of cytokines and/or the release and/or synthesis of lipid mediators such as leukotrienes and prostaglandins.
- the present invention provides methods of treating and/or preventing diseases characterized by, caused by or associated with the release of chemical mediators as a consequence of activating Fc receptor signaling cascades, such as FceRI and/or Fc ⁇ RI- signaling cascades.
- the methods may be practiced in animals in veterinary contexts or in humans.
- the methods generally involve administering to an animal subject or human an amount of a 2,4-pyrimidinediamine compound or prodrug of the invention, or an acceptable salt, hydrate, solvate, N-oxide and/or composition thereof, effective to treat or prevent the disease.
- activation of the FceRI or Fc ⁇ RI signaling cascade leads to the immediate (i.e., within 1-3 min. of receptor activation) release of preformed mediators of atopic and/or Type I hypersensitivity reactions (e.g, histamine, proteases such as tryptase, etc.) via the degranulation process.
- atopic and/or Type I hypersensitivity reactions e.g, histamine, proteases such as tryptase, etc.
- Such atopic or Type I hypersensitivity reactions include, but are not limited to, anaphylactic reactions to environmental and other allergens (e.g., pollens, insect and/or animal venoms, foods, drugs, contrast dyes, etc.), anaphylactoid reactions, hay fever, allergic conjunctivitis, allergic rhinitis, allergic asthma, atopic dermatitis, eczema, urticaria, mucosal disorders, tissue disorders and certain gastrointestinal disorders.
- allergens e.g., pollens, insect and/or animal venoms, foods, drugs, contrast dyes, etc.
- anaphylactoid reactions hay fever, allergic conjunctivitis, allergic rhinitis, allergic asthma, atopic dermatitis, eczema, urticaria, mucosal disorders, tissue disorders and certain gastrointestinal disorders.
- the immediate release of the preformed mediators via degranulation is followed by the release and/or synthesis of a variety of other chemical mediators, including, among other things, platelet activating factor (PAF), prostaglandins and leukotrienes (e.g., LTC4) and the de novo synthesis and release of cytokines such as TNF ⁇ , IL-4, IL-5, IL-6, IL-13, etc.
- PAF platelet activating factor
- prostaglandins and leukotrienes e.g., LTC4
- cytokines such as TNF ⁇ , IL-4, IL-5, IL-6, IL-13, etc.
- the first of these two processes occurs approximately 3-30 min. following receptor activation; the latter approximately 30 min. - 7 hrs. following receptor activation.
- These "late stage” mediators are thought to be in part responsible for the chronic symptoms of the above-listed atopic and Type I hypersensitivity reactions, and in addition are chemical mediators of inflammation and inflammatory diseases (e.g., osteoarthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, idiopathic inflammatory bowel disease, irritable bowel syndrome, spastic colon, etc.), low grade scarring (e.g., scleroderma, increased fibrosis, keloids, post-surgical scars, pulmonary fibrosis, vascular spasms, migraine, reperfusion injury and post myocardial infarction), and sicca complex or syndrome. All of these diseases may be treated or prevented according to the methods of the invention.
- inflammatory diseases e.g., osteoarthritis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, idiopathic inflammatory bowel disease, irritable bowel syndrome, spastic colon, etc.
- low grade scarring e.
- Additional diseases which can be treated or prevented according to the methods of the invention include diseases associated with basophil cell and/or mast cell pathology.
- diseases associated with basophil cell and/or mast cell pathology include, but are not limited to, diseases of the skin such as scleroderma, cardiac diseases such as post myocardial infarction, pulmonary diseases such as pulmonary muscle changes or remodeling and chronic obstructive pulmonary disease (COPD) and diseases of the gut such as inflammatory bowel syndrome (spastic colon).
- the 2,4-pyrimidinediamine compounds of the invention are also potent inhibitors of the tyrosine kinase Syk kinase.
- the present invention provides methods of regulating, and in particular inhibiting, Syk kinase activity.
- the method generally involves contacting a Syk kinase or a cell comprising a Syk kinase with an amount of a 2,4-pyrimidinediamine compound or prodrug of the invention, or an acceptable salt, hydrate, solvate, N-oxide and or composition thereof, effective to regulate or inhibit Syk kinase activity.
- the Syk kinase is an isolated or recombinant Syk kinase.
- the Syk kinase is an endogenous or recombinant Syk kinase expressed by a cell, for example a mast cell or a basophil cell.
- the method may be practiced in in vitro contexts or in in vivo contexts as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by or associated with Syk kinase activity.
- the 2,4-pyrimdinediamine compounds of the invention inhibit cellular degranulation and/or the release of other chemical mediators primarily by inhibiting Syk kinase that gets activated through the gamma chain homodimer of FceRI (yee, e.g., FIG. 2).
- This gamma chain homodimer is shared by other Fc receptors, including Fc ⁇ RI, Fc ⁇ RIII and FcoRI. For all of these receptors, intracellular signal transduction is mediated by the common gamma chain homodimer.
- Binding and aggregation of those receptors results in the recruitment and activation of tyrosine kinases such as Syk kinase.
- the 2,4-pyrimidinediamine compounds described herein may be used to regulate, and in particular inhibit, the signaling cascades of Fc receptors having this gamma chain homodimer, such as FceRI, Fc ⁇ RI, Fc ⁇ RIII and FcoRI, as well as the cellular responses elicited through these receptors.
- Syk kinase is known to play a critical role in other signaling cascades.
- Syk kinase is an effector of B-cell receptor (BCR) signaling (Turner et al., 2000, Immunology Today 21 : 148-154) and is an essential component of integrin beta(l), beta(2) and beta(3) signaling in neutrophils (Mocsai et al, 2002, Immunity 16:547-558).
- BCR B-cell receptor
- 2,4-pyrimidinediamine compounds described herein are potent inhibitors of Syk kinase, they can be used to regulate, and in particular inhibit, any signaling cascade where Syk plays a role, such as, fore example, the Fc receptor, BCR and integrin signaling cascades, as well as the cellular responses elicited through these signaling cascades.
- any signaling cascade where Syk plays a role such as, fore example, the Fc receptor, BCR and integrin signaling cascades, as well as the cellular responses elicited through these signaling cascades.
- the particular cellular response regulated or inhibited will depend, in part, on the specific cell type and receptor signaling cascade, as is well known in the art.
- Non-limiting examples of cellular responses that may be regulated or inhibited with the 2,4-pyrimidinediamine compounds include a respiratory burst, cellular adhesion, cellular degranulation, cell spreading, cell migration, phagocytosis (e.g., in macrophages), calcium ion flux (e.g., in mast, basophil, neutrophil, eosinophil and B-cells), platelet aggregation, and cell maturation (e.g., in B- cells).
- the present invention provides methods of regulating, and in particular inhibiting, signal transduction cascades in which Syk plays a role.
- the method generally involves contacting a Syk-dependent receptor or a cell expressing a Syk- dependent receptor with an amount of a 2,4-pyrimidinediamine compound or prodrug of the invention, or an acceptable salt, hydrate, solvate, N-oxide and/or composition thereof, effective to regulate or inhibit the signal transduction cascade.
- the methods may also be used to regulate, and in particular inhibit, downstream processes or cellular responses elicited by activation of the particular Syk-dependent signal transduction cascade.
- the methods may be practiced to regulate any signal transduction cascade where Syk is not known or later discovered to play a role.
- the methods may be practiced in in vitro contexts or in in vivo contexts as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by or associated with activation of the Syk-dependent signal transduction cascade.
- diseases characterized by, caused by or associated with activation of the Syk-dependent signal transduction cascade.
- Non-limited examples of such diseases include those previously discussed.
- the methods generally involve administering to a subject suffering from an autoimmune disease or at risk of developing an autoimmune disease an amount of a 2,4- pyrimidinediamine method or prodrug of the invention, or an acceptable salt, N-oxide, hydrate, solvate or composition thereof, effective to treat or prevent the autoimmune disease and/or its associated symptoms.
- Autoimmune diseases that can be treated or prevented with the 2,4-pyrimidinediamine compounds include those diseases that are commonly associated with nonanaphylactic hypersensitivity reactions (Type II, Type III and/or Type IV hypersensitivity reactions) and/or those diseases that are mediated, at least in part, by activation of the Fc ⁇ R signaling cascade in monocyte cells.
- Such autoimmune disease include, but are not limited to, those autoimmune diseases that are frequently designated as single organ or single cell-type autoimmune disorders and those autoimmune disease that are frequently designated as involving systemic autoimmune disorder.
- Non-limiting examples of diseases frequently designated as single organ or single cell-type autoimmune disorders include: Hashimoto's thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia, myasthenia gravis, Graves' disease, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous glomerulopathy.
- Non-limiting examples of diseases often designated as involving systemic autoimmune disorder include: systemic lupus erythematosis, rheumatoid arthritis, Sjogren's syndrome, Reiter's syndrome, polymyositis- dermatomyositis, systemic sclerosis, polyarteritis nodosa, multiple sclerosis and bullous pemphigoid. 5.
- FIG. 1 provides a cartoon illustrating allergen-induced production of IgE and consequent release of preformed and other chemical mediators from mast cells;
- FIG. 2 provides a cartoon illustrating the Fc ⁇ Rl signal transduction cascade leading to degranulation of mast and/or basophil cells
- FIG. 3 provides a cartoon illustrating the putative points of action of compounds that selectively inhibit upstream FceRI-mediated degranulation and compounds that inhibit both FceRI-mediated and ionomycin-induced degranulation;
- FIG. 4 provides graphs illustrating the effects of certain 2,4-pyrimidinediamine compounds, DMSO (control) and ionomycin on Ca 2+ flux in CHMC cells;
- FIG. 5 provides graphs illustrating the immediacy of the inhibitory activity of compounds R921218 and R926495;
- FIG. 6 provides a graph illustrating the effect of washout on the inhibitory activity of compounds R921218 and R921302;
- FIG. 7 provides data showing that varying concentrations of compounds R921218 (A) and R921219 (B) inhibit phosporylation of various proteins downstream of Syk kinase in the IgE receptor signal transduction cascade in activated BMMC cells;
- FIG. 8 provides data showing dose responsive inhibition of Syk kinase phosphorylation of an endogenous substrate (LAT) and a peptide substrate in the presence of increasing concentrations of compounds R921218 (X), R921219 (Y) and R921304 (Z);
- FIG. 9 provides data showing that the inhibition of Syk kinase by compound
- R921219 is ATP competitive
- FIG. 10 provides data showing that varying concentrations of compounds R921219 (A) and R218218 (B) inhibit phosphorylation of proteins downstream of Syk kinase, but not LYN kinase, in the FceRI signal transduction cascade in activated CHMC cells; also shown is inhibition of phosphorylation of proteins downstream of LYN kinase but not Syk kinase, in the presence of a known LYN kinase inhibitor (PP2);
- PP2 LYN kinase inhibitor
- FIGS. 11A-D provide data showing inhibition of phosphorylation of proteins downstream of Syk kinase in the FceRI signal transduction cascade in BMMC cells;
- FIG. 12 is a graph illustrating the efficacy of compound R921302 in a mouse model of collagen antibody-induced arthritis ("CAIA");
- FIG. 13 is a graph illustrating the efficacy of compound R921302 in the CAIA model as compared to other agents and control agents;
- FIG. 14 is a graph illustrating the efficacy of compound R921302 in a rat model of collagen-induced arthritis ("CIA");
- FIG. 15 is a graph illustrating the efficacy of compound R921302 in inhibiting experimental autoimmune encephalomyehtis ("EAE") in mice, a clinical model for multiple sclerosis; and
- FIG. 16 is a graph illustrating the efficacy compound R921302 on SJL mice treated on the starting day of immunization with 150 ⁇ g PLP 139-151/200 ⁇ g MTB (CFA).
- Alkyl by itself or as part of another substituent refers to a saturated or unsaturated branched, straight-chain or cyclic monovalent hydrocarbon radical having the stated number of carbon atoms (i.e., C1-C6 means one to six carbon atoms) that is derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne.
- Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop- 1 -en- 1-yl, prop-l-en-2-yl, prop-2-en-l-yl, cycloprop-1-en-l-yl; cycloprop-2-en-l-yl, prop- 1-yn- 1-yl , prop-2-yn-l-yl, etc.; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-l-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, but- 1 -en- 1-yl, but-l-en-2-yl, 2-methyl-prop-l-en-yl, but-2-en-l-yl ,
- alkanyl by itself or as part of another substituent refers to a saturated branched, straight-chain or cyclic alkyl derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane.
- Typical alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyls such as propan-1-yl, propan-2-yl (isopropyl), cyclopropan-1-yl, etc.; butanyls such as butan-1-yl, butan-2-yl (sec-bxxtyT), 2-methyl-propan-l-yl (isobutyl), 2-methyl-propan-2-yl (t-butyl), cyclobutan-1-yl, etc.; and the like.
- the alkanyl groups are (C1-C6) alkanyl.
- "Alkenyl” by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl having at least one carbon-carbon double bond derived by the removal of one hydrogen a'tom from a single carbon atom of a parent alkene.
- the group may be in either the cis or trans conformation about the double bond(s).
- Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop- 1 -en- 1-yl , prop- 1 -en-2-yl, prop-2-en- 1 -yl, prop-2-en-2-yl, cycloprop- 1 -en- 1 -yl; cycloprop-2-en- 1 -yl ; butenyls such as but- 1 -en- 1-yl, but-l-en-2-yl, 2-methyl-prop-l-en-l-yl, but-2-en-l-yl, but-2-en-2-yl, buta-l,3-dien-l-yl, buta-l,3-dien-2-yl, cyclobut-1-en-l-yl, cyclobut-l-en-3-yl, cyclobuta-l,3-dien-l-yl, etc.; and the like.
- the alkenyl group is (C2-C6) alkenyl.
- "Alkynyl" by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne.
- Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop- 1-yn- 1-yl , ⁇ rop-2-yn-l-yl, etc.; butynyls such as but- 1-yn- 1-yl, but-l-yn-3-yl, but-3-yn-l-yl , etc.; and the like.
- the alkynyl group is (C2-C6) alkynyl.
- Alkyldiyl by itself or as part of another substituent refers to a saturated or unsaturated, branched, straight-chain or cyclic divalent hydrocarbon group having the stated number of carbon atoms (i.e., C1-C6 means from one to six carbon atoms) derived by the removal of one hydrogen atom from each of two different carbon atoms of a parent alkane, alkene or alkyne, or by the removal of two hydrogen atoms from a single carbon atom of a parent alkane, alkene or alkyne.
- the two monovalent radical centers or each valency of the divalent radical center can form bonds with the same or different atoms.
- Typical alkyldiyl groups include, but are not limited to, methandiyl; ethyldiyls such as ethan-l,l-diyl, ethan-l,2-diyl, ethen-l,l-diyl, ethen-l,2-diyl; propyldiyls such as propan-l,l-diyl, propan-l,2-diyl, propan-2,2-diyl, propan-l,3-diyl, cyclopropan-l,l-diyl, cyclopropan-l,2-diyl, prop-l-en-l,l-diyl, prop-l-en-l,2-diyl, prop-2-en-l,2-diyl, prop- 1 -en- 1 ,3 -diyl, cycloprop- 1 -en- 1 ,2-diyl, cyclo
- alkanyldiyl alkenyldiyl and/or alkynyldiyl
- alkylidene alkylidene
- saturated acyclic alkanyldiyl groups in which the radical centers are at the terminal carbons, e.g., methandiyl (methano); ethan-l,2-diyl (ethano); propan-l,3-diyl (propano); butan- 1,4-diyl (butano); and the like (also referred to as alkylenos, defined infra).
- Alkyleno by itself or as part of another substituent refers to a straight-chain saturated or unsaturated alkyldiyl group having two terminal monovalent radical centers derived by the removal of one hydrogen atom from each of the two terminal carbon atoms of straight-chain parent alkane, alkene or alkyne.
- the locant of a double bond or triple bond, if present, in a particular alkyleno is indicated in square brackets.
- Typical alkyleno groups include, but are not limited to, methano; ethylenos such as ethano, etheno, ethyno; propylenos such as propano, prop[l]eno, propa[l,2]dieno, prop[l]yno, etc.; butylenos such as butano, but[l]eno, but[2]eno, buta[l,3]dieno, but[l]yno, but[2]yno, buta[l,3]diyno, etc.; and the like. Where specific levels of saturation are intended, the nomenclature alkano, alkeno and/or alkyno is used.
- the alkyleno group is (C1-C6) or (C1-C3) alkyleno. Also preferred are straight-chain saturated alkano groups, e.g., methano, ethano, propano, butano, and the like.
- Heteroalkyl Heteroalkanyl
- Heteroalkenyl Heteroalkynyl
- Heteroalkyldiyl Heteroalkyleno
- alkyl, alkanyl, alkenyl, alkynyl, alkyldiyl and alkyleno groups respectively, in which one or more of the carbon atoms are each independently replaced with the same or different heteratoms or heteroatomic groups.
- Typical heteroatoms and/or heteroatomic groups which can replace the carbon atoms include, but are not limited to, -O-, -S-, -S-O-, -NR'-, -PH-, -S(O)-, -S(O) 2 -, -S(O) NR'-, -S(O) 2 NR'-, and the like, including combinations thereof, where each R' is independently hydrogen or (C1-C6) alkyl.
- Cycloalkyl and Heterocycloalkyl by themselves or as part of another substituent refer to cyclic versions of “alkyl” and “heteroalkyl” groups, respectively.
- Typical cycloalkyl groups include, but are not limited to, cyclopropyl; cyclobutyls such as cyclobutanyl and cyclobutenyl; cyclopentyls such as cyclopentanyl and cyclopentenyl; cyclohexyls such as cyclohexanyl and cyclohexenyl; and the like.
- Typical heterocycloalkyl groups include, but are not limited to, tetrahydrofuranyl (e.g. , tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, etc.), piperidinyl (e.g., piperidin-1-yl, piperidin- 2-yl, etc.), morpholinyl (e.g., morpholin-3-yl, mo ⁇ pholin-4-yl, etc.), piperazinyl (e.g., piperazin-1-yl, piperazin-2-yl, etc.), and the like.
- tetrahydrofuranyl e.g. , tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, etc.
- piperidinyl e.g., piperidin-1-yl, piperidin- 2-yl, etc.
- morpholinyl e.g., morpholin-3-y
- Acyclic Heteroatomic Bridge refers to a divalent bridge in which the backbone atoms are exclusively heteroatoms and/or heteroatomic groups.
- Typical acyclic heteroatomic bridges include, but are not limited to, -O-, -S-, -S-O-, -NR'-, -PH-, -S(O)-, -S(O) 2 -, -S(O) NR'-, -S(O) 2 NR'-, and the like, including combinations thereof, where each R' is independently hydrogen or (C1-C6) alkyl.
- Parent aromatic ring system refers to an unsaturated cyclic or polycyclic ring system having a conjugated ⁇ electron system.
- parent aromatic ring system fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, fluorene, indane, indene, phenalene, tetrahydronaphthalene, etc.
- Typical parent aromatic ring systems include, but are not limited to, aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, tetrahydronaphthalene, triphenylene, trinaphthalene, and the like, as well as
- Aryl by itself or as part of another substituent refers to a monovalent aromatic hydrocarbon group having the stated number of carbon atoms (i.e., C5-C15 means from 5 to 15 carbon atoms) derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
- Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, ⁇ s-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like, as well as the various hydro is
- the aryl group is (C5-C15) aryl, with (C5-C10) being even more preferred.
- Particularly preferred aryls are cyclopentadienyl, phenyl and naphthyl.
- “Arylaryl” by itself or as part of another substituent refers to a monovalent hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a ring system in which two or more identical or non-identical parent aromatic ring systems are joined directly together by a single bond, where the number of such direct ring junctions is one less than the number of parent aromatic ring systems involved.
- Typical arylaryl groups include, but are not limited to, biphenyl, triphenyl, phenyl-naphthyl, binaphthyl, biphenyl-naphthyl, and the like. Where the number of carbon atoms in an arylaryl group are specified, the numbers refer to the carbon atoms comprising each parent aromatic ring.
- (C5-C15) arylaryl is an arylaryl group in which each aromatic ring comprises from 5 to 15 carbons, e.g., biphenyl, triphenyl, binaphthyl, phenylnaphthyl, etc.
- each parent aromatic ring system of an arylaryl group is independently a (C5-C15) aromatic, more preferably a (C5-C10) aromatic.
- arylaryl groups in which all of the parent aromatic ring systems are identical e.g., biphenyl, triphenyl, binaphthyl, trinaphthyl, etc.
- Biaryl by itself or as part of another substituent refers to an arylaryl group having two identical parent aromatic systems joined directly together by a single bond.
- Typical biaryl groups include, but are not limited to, biphenyl, binaphthyl, bianthracyl, and the like.
- the aromatic ring systems are (C5-C15) aromatic rings, more preferably (C5-C10) aromatic rings.
- a particularly preferred biaryl group is biphenyl.
- Arylalkyl by itself or as part of another substituent refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an aryl group.
- Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-l-yl, 2-phenylethen-l-yl, naphthylmethyl, 2-naphthylethan- 1 -yl, 2-naphthylethen- 1 -yl, naphthobenzyl, 2-naphthophenylethan- 1 -yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, arylakenyl and/or arylalkynyl is used.
- the arylalkyl group is (C6-C21) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C1-C6) and the aryl moiety is (C5-C15).
- the arylalkyl group is (C6-C13), e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C1-C3) and the aryl moiety is (C5-C10).
- Parent Heteroaromatic Ring System refers to a parent aromatic ring system in which one or more carbon atoms are each independently replaced with the same or different heteroatoms or heteroatomic groups. Typical heteroatoms or heteroatomic groups to replace the carbon atoms include, but are not limited to, N, NH, P, O, S, S(O), S(O) 2 , Si, etc. Specifically included within the definition of "parent heteroaromatic ring systems” are fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, benzodioxan, benzofuran, chromane, chromene, indole, indoline, xanthene, etc.
- parent heteroaromatic ring system those recognized rings that include common substituents, such as, for example, benzopyrone and l-methyl-l,2,3,4-tetrazole.
- benzene rings fused to cyclic polyalkylene glycols such as cyclic polyethylene glycols.
- Typical parent heteroaromatic ring systems include, but are not limited to, acridine, benzimidazole, benzisoxazole, benzodioxan, benzodioxole, benzofuran, benzopyrone, benzothiadiazole, benzothiazole, benzotriazole, benzoxaxine, benzoxazole, benzoxazoline, carbazole, ⁇ -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine,
- Heteroaryl by itself or as part of another substituent refers to a monovalent heteroaromatic group having the stated number of ring atoms (e.g., “5-14 membered” means from 5 to 14 ring atoms) derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system.
- Typical heteroaryl groups include, but are not limited to, groups derived from acridine, benzimidazole, benzisoxazole, benzodioxan, benzodiaxole, benzofuran, benzopyrone, benzothiadiazole, benzothiazole, benzotriazole, benzoxazine, benzoxazole, benzoxazoline, carbazole, ⁇ -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridme, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pter
- Heteroaryl-Heteroaryl by itself or as part of another substituent refers to a monovalent heteroaromatic group derived by the removal of one hydrogen atom from a single atom of a ring system in which two or more identical or non-identical parent heteroaromatic ring systems are joined directly together by a single bond, where the number of such direct ring junctions is one less than the number of parent heteroaromatic ring systems involved.
- Typical heteroaryl-heteroaryl groups include, but are not limited to, bipyridyl, tripyridyl, pyridylpurinyl, bipurinyl, etc.
- each parent heteroaromatic ring system comprises from 5 to 15 atoms, e.g., bipyridyl, tripuridyl, etc.
- each parent heteroaromatic ring system is independently a 5-15 membered heteroaromatic, more preferably a 5-10 membered heteroaromatic.
- heteroaryl-heteroaryl groups in which all of the parent heteroaromatic ring systems are identical.
- “Biheteroar l” by itself or as part of another substituent refers to a heteroaryl-heteroaryl group having two identical parent heteroaromatic ring systems joined directly together by a single bond.
- Typical biheteroaryl groups include, but are not limited to, bipyridyl, bipurinyl, biquinolinyl, and the like.
- the heteroaromatic ring systems are 5-15 membered heteroaromatic rings, more preferably 5-10 membered heteroaromatic rings.
- Heteroarylalkyl by itself or as part of another substituent refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylakenyl and/or heteroarylalkynyl is used.
- the heteroarylalkyl group is a 6-21 membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is (C1-C6) alkyl and the heteroaryl moiety is a 5-15-membered heteroaryl.
- the heteroarylalkyl is a 6-13 membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety is (C1-C3) alkyl and the heteroaryl moiety is a 5-10 membered heteroaryl.
- Halogen or “Halo” by themselves or as part of another substituent, unless otherwise stated, refer to fluoro, chloro, bromo and iodo.
- Haloalkyl by itself or as part of another substituent refers to an alkyl group in which one or more of the hydrogen atoms is replaced with a halogen.
- haloalkyl is meant to include monohaloalkyls, dihaloalkyls, trihaloalkyls, etc. up to perhaloalkyls.
- (C1-C2) haloalkyl includes fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 1,1-difluoroethyl, 1,2-difluoroethyl, 1,1,1 -trifluoroethyl, perfluoroethyl, etc .
- alkyloxy or “alkoxy” refers to a group of the formula -OR
- alkylamine refers to a group of the formula -NHR
- dialkylamine refers to a group of the formula -NR"R
- each R is independently an alkyl
- haloalkoxy or “haloalkyloxy” refers to a group of the formula -OR'", where R'" is a haloalkyl.
- Protecting group refers to a group of atoms that, when attached to a reactive functional group in a molecule, mask, reduce or prevent the reactivity of the functional group. Typically, a protecting group may be selectively removed as desired during the course of a synthesis. Examples of protecting groups can be found in Greene and Wuts, Protective Groups in Organic Chemistry, 3 rd Ed., 1999, John Wiley & Sons, NY and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8, 1971-1996, John Wiley & Sons, NY.
- Representative amino protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsilyl-ethanesulfonyl (“TES”), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“FMOC”), nitro- veratryloxycarbonyl (“NVOC”) and the like.
- hydroxyl protecting groups include, but are not limited to, those where the hydroxyl group is either acylated or alkylated such as benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (e.g., TMS or TIPPS groups) and allyl ethers.
- Prodrug refers to a derivative of an active 2,4-pyrimidinediamine compound (drug) that requires a transformation under the conditions of use, such as within the body, to release the active 2,4-pyrimidinediamine drug.
- Prodrugs are frequently, but not necessarily, pharmacologically inactive until converted into the active drug.
- Prodrugs are typically obtained by masking a functional group in the 2,4-pyrimidinediamine drug believed to be in part required for activity with a progroup (defined below) to form a promoiety which undergoes a transformation, such as cleavage, under the specified conditions of use to release the functional group, and hence the active 2,4-pyrimidinediamine drug.
- the cleavage of the promoiety may proceed spontaneously, such as by way of a hydrolysis reaction, or it may be catalyzed or induced by another agent, such as by an enzyme, by light, by acid or base, or by a change of or exposure to a physical or environmental parameter, such as a change of temperature.
- the agent may be endogenous to the conditions of use, such as an enzyme present in the cells to which the prodrug is administered or the acidic conditions of the stomach, or it may be supplied exogenously.
- progroups as well as the resultant promoieties, suitable for masking functional groups in the active 2,4-pyrimidinediamines compounds to yield prodrugs are well-known in the art.
- a hydroxyl functional group may be masked as a sulfonate, ester or carbonate promoiety, which may be hydrolyzed in vivo to provide the hydroxyl group.
- An amino functional group may be masked as an amide, carbamate, imine, urea, phosphenyl, phosphoryl or sulfenyl promoiety, which may be hydrolyzed in vivo to provide the amino group.
- a carboxyl group may be masked as an ester (including silyl esters and thioesters), amide or hydrazide promoiety, which may be hydrolyzed in vivo to provide the carboxyl group.
- ester including silyl esters and thioesters
- amide or hydrazide promoiety which may be hydrolyzed in vivo to provide the carboxyl group.
- suitable progroups and their respective promoieties will be apparent to those of skill in the art.
- Progroup refers to a type of protecting group that, when used to mask a functional group within an active 2,4-pyrimidinediamine drug to form a promoiety, converts the drug into a prodrug.
- Progroups are typically attached to the functional group of the drug via bonds that are cleavable under specified conditions of use.
- a progroup is that portion of a promoiety that cleaves to release the functional group under the specified conditions of use.
- an amide promoiety of the formula -NH-C(O)CH 3 comprises the progroup -C(O)CH 3 .
- Fc Receptor refers to a member of the family of cell surface molecules that binds the Fc portion (containing the specific constant region) of an immunoglobulin. Each Fc receptor binds immunoglobulins of a specific type. For example the Fco; receptor (“Fc ⁇ R”) binds IgA, the FceR binds IgE and the Fc ⁇ R binds IgG.
- the FcoR family includes the polymeric Ig receptor involved in epithelial transport of IgA/IgM, the myeloid specific receptor RcoRI (also called CD89), the Fc ⁇ ⁇ R and at least two alternative IgA receptors (for a recent review see Monteiro & van de Winkel, 2003, Annu. Rev.
- the FcoRI is expressed on neutrophils, eosinophils, moncytes/macrophages, dendritic cells and kupfer cells.
- the FcoRI indues one alpha chain and the FcR gamma homodimer that bears an activation motif (ITAM) in the cytoplasmic domain and phosphorylates Syk kinase.
- ITAM activation motif
- the FceR family includes two types, designated FceRI and FceRII (also known as CD23).
- FceRI is a high affinity receptor (binds IgE with an affinity of about 10 10 M _1 ) found on mast, basophil and eosinophil cells that anchors monomeric IgE to the cell surface.
- the FceRI possesses one alpha chain, one beta chain and the gamma chain homodimer discussed above.
- the FceRII is a low affinity receptor expressed on mononuclear phagocytes, B lymphocytes, eosinophils and platelets.
- the FceRII comprises a single polypeptide chain and does not include the gamma chain homodimer.
- Fc ⁇ RI also known as CD64
- Fc ⁇ RII also known as CD32
- Fc ⁇ RIII also known as CDl 6
- Fc ⁇ RI is a high affinity receptor (binds IgGl with an affinity of 10 8 M _1 ) found on mast, basophil, mononuclear, embarkophil, eosinophil, deudritic and phagocyte cells that anchors nomomeric IgG to the cell surface.
- the Fc ⁇ RI includes one alpha chain and the gamma chain dimer shared by FcoRI and FceRI.
- the Fc ⁇ RII is a low affinity receptor expressed on neutrophils, monocytes, eosinophils, platelets and B lymphocytes.
- the Fc ⁇ RII includes one alpha chain, and does not include the gamma chain homodimer discussed above.
- the Fc ⁇ RIII is a low affinity (bindes IgGl with an affinity of 5xl0 5 M _1 ) expressed on NK, eosinophil, macrophage, neutrophil and mast cells. It comprises one alpha chain and the gamma homodimer shared by FcoRI, FceRI and Fc ⁇ RI.
- Fc Receptor-Mediated Degranulation or “Fc Receptor-Induced Degranulation” refers to degranulation that proceeds via an Fc receptor signal transduction cascade initiated by crosslinking of an Fc receptor.
- IgE-Induced Degranulation or “FceRI-Mediated Degranulation” refers to degranulation that proceeds via the IgE receptor signal transduction cascade initiated by crosslinking of Fc ⁇ Rl -bound IgE.
- the crosslinking may be induced by an IgE-specific allergen or other multivalent binding agent, such as an anti-IgE antibody.
- the FceRI signaling cascade leading to degranulation may be broken into two stages: upstream and downstream.
- the upstream stage includes all of the processes that occur prior to calcium ion mobilization (illustrated as "Ca 2+ " in FIG. 2; see also FIG. 3).
- the downstream stage includes calcium ion mobilization and all processes downstream thereof.
- Compounds that inhibit FceRI-mediated degranulation may act at any point along the FceRI-mediated signal transduction cascade.
- Compounds that selectively inhibit upstream FceRI-mediated degranulation act to inhibit that portion of the FceRI signaling cascade upstream of the point at which calcium ion mobilization is induced.
- compounds that selectively inhibit upstream FceRI-mediated degranulation inhibit degranulation of cells such as mast or basophil cells that are activated or stimulated with an IgE-specific allergen or binding agent (such as an anti-IgE antibody) but do not appreciably inhibit degranulation of cells that are activated or stimulated with degranulating agents that bypass the FceRI signaling pathway, such as, for example the calcium ionophores ionomycin and A23187.
- IgG-Induced Degranulation or “Fc ⁇ RI-Mediated Degranulation” refers to degranulation that proceeds via the Fc ⁇ RI signal transduction cascade initiated by crosslinking of Fc ⁇ RI-bound IgG.
- the crosslinking may be induced by an IgG-specific allergen or another multivalent binding agent, such as an anti-IgG or fragment antibody.
- the Fc ⁇ RI signaling cascade also leads to degranulation which may be broken into the same two stages: upstream and downstream. Similar to FceRI-mediated degranulation, compounds that selectively inhibit upstream Fc ⁇ RI-mediated degranulation act upstream of the point at which calcium ion mobilization is induced.
- compounds that selectively inhibit upstream Fc ⁇ RI-mediated degranulation inhibit degranulation of cells such as mast or basophil cells that are activated or stimulated with an IgG-specific allergen or binding agent (such as an anti-IgG antibody or fragment) but do not appreciably inhibit degranulation of cells that are activated or stimulated with degranulating agents that bypass the Fc ⁇ RI signaling pathway, such as, for example the calcium ionophores ionomycin and A23187.
- Ionophore-Induced Degranulation or “Ionophore-Mediated Degranulation” refers to degranulation of a cell, such as a mast or basophil cell, that occurs upon exposure to a calcium ionophore such as, for example, ionomycin or A23187.
- Syk Kinsase refers to the well-known 72kDa non-receptor (cytoplasmic) spleen protein tyrosine kinase expressed in B-cells and other hematopoetic cells. Syk kinase includes two consensus Src-homology 2 (SH2) domains in tandem that bind to phosphorylated immunoreceptor tyrosine-based activation motifs ("ITAMs”), a "linker” domain and a catalytic domain (for a review of the structure and function of Syk kinase see Sada et al, 2001, J. Biochem. (Tokyo) 130:177-186); see also Turner et al, 2000, Immunology Today 21:148-154).
- SH2 consensus Src-homology 2
- Syk kinase has been extensively studied as an effector of B-cell receptor (BCR) signaling (Turner et al, 2000, supra). Syk kinase is also critical for tyrosine phosphorylation of multiple proteins which regulate important pathways leading from immunoreceptors, such as Ca 2+ mobilization and mitogen-activated protein kinase
- MNK methyl kinase cascades (see, e.g., FIG. 2) and degranulation. Syk kinase also plays a critical role in integrin signaling in neutrophils (see, e.g., Mocsai et al. 2002, Immunity 16:547-558).
- Syk kinase includes kinases from any species of animal, including but not limited to, homosapiens, simian, bovine, porcine, rodent, etc., recognized as belonging to the Syk family. Specifically included are isoforms, splice variants, allelic variants, mutants, both naturally occuring and man-made. The amino acid sequences of such Syk kinases are well known and available from GENBANK. Specific examples of mRNAs encoding different isoforms of human Syk kinase can be found at GENBANK accession no.
- tyrosine kinases belonging to other families may have active sites or binding pockets that are similar in three-dimensional structure to that of
- Syk mimics are expected to catalyze phosphorylation of substrates phosphorylated by Syk.
- Syk mimics signal transduction cascades in which such Syk mimics play a role and biological responses effected by such Syk mimics and Syk mimic-dependent signaling cascades may be regulated, and in particular inhibited, with the
- Synk-Dependent Signaling Cascade refers to a signal transduction cascade in which
- Syk kinase plays a role.
- Non-limiting examples of such Syk-dependent signaling cascades include the FcoRI, FceRI, Fc ⁇ RI, Fc ⁇ RIII, BCR and integrin signaling cascades.
- Autoimmune Disease refers to those diseases which are commonly associated with the nonanaphylactic hypersensitivity reactions (Type II, Type III and/or Type IV hypersensitivity reactions) that generally result as a consequence of the subject's own humoral and/or cell-mediated immune response to one or more immunogenic substances of endogenous and/or exogenous origin. Such autoimmune diseases are distinguished from diseases associated with the anaphylactic (Type I or IgE-mediated ) hypersensitivity reactions.
- the compounds of the invention are generally 2,4-pyrimidinediamine compounds according to structural formula (I):
- L and L are each, independently of one another, selected from the group consisting of a direct bond and a linker;
- R 2 is selected from the group consisting of (C1-C6) alkyl optionally substituted with one or more of the same or different R 8 groups, (C3-C8) cycloalkyl optionally substituted with one or more of the same or different R 8 groups, cyclohexyl optionally substituted with one or more of the same or different R 8 groups, 3-8 membered cycloheteroalkyl optionally substituted with one or more of the same or different R 8 groups, (C5-C15) aryl optionally substituted with one or more of the same or different R 8 groups, phenyl optionally substituted with one or more of the same or different R 8 groups and 5-15 membered heteroaryl optionally substituted with one or more of the same or different R 8 groups;
- R 4 is selected from the group consisting of hydrogen, (C1-C6) alkyl optionally substituted with one or more
- R 5 is selected from the group consisting of R 6 , (C1-C6) alkyl optionally substituted with one or more of the same or different R 8 groups, (C1-C4) alkanyl optionally substituted with one or more of the same or different R 8 groups, (C2-C4) alkenyl optionally substituted with one or more of the same or different R 8 groups and (C2-C4) alkynyl optionally substituted with one or more of the same or different R groups; each R 6 is independently selected from the group consisting of hydrogen, an electronegative group, -OR d , -SR d , (C1-C3) haloalkyloxy, (C1-C3) perhaloalkyloxy, -NR C R C , halogen, (C1-C3) haloalkyl,(Cl-C3) perhaloalkyl, -CF 3 , -CH 2 CF 3 , -CF 2 CF 3 , -CN, -NC, -OCN
- R 8 is selected from the group consisting of R , R , R a substituted with one or more of the same or different R a or R , -OR a substituted with one or more of the same or different R a or R b , -B(OR a ) 2 , -B(NR C R C ) 2 , -(CH 2 ) m -R b , -(CHR -R b , -O-(CH 2 ) m -R b , -S-(CH 2 ) W -R b , -O-CHR a R b , -O-CR a (R b ) 2 , -O-(CHR -R b , -O- (CH 2 ) m -CH[(CH 2 ) m R b ]R b , -S-(CHR a ) m -R b , -C(O)NH-(
- L 1 and L 2 represent, independently of one another, a direct bond or a linker.
- the substituents R 2 and/or R 4 may be bonded either directly to their respective nitrogen atoms or, alternatively, spaced away from their respective nitrogen atoms by way of a linker.
- the identity of the linker is not critical and typical suitable linkers include, but are not limited to, (C1-C6) alkyldiyls, (C1-C6) alkanos and (C1-C6) heteroalkyldiyls, each of which may be optionally substituted with one or more of the same or different R 8 groups, where R 8 is as previously defined for structural formula (I).
- L 1 and L 2 are each, independently of one another, selected from the group consisting of a direct bond, (C1-C3) alkyldiyl optionally substituted with one or more of the same or different R a , suitable R b or R 9 groups and 1-3 membered heteroalkyldiyl optionally substituted with one or more of the same or different R a , suitable R b or R 9 groups, wherem R 9 is selected from the group consisting of (C1-C3) alkyl, -OR a , -C(O)OR a , (C5-C10) aryl optionally substituted with one or more of the same or different halogens, phenyl optionally substituted with one or more of the same or different halogens, 5-10 membered heteroaryl optionally substituted with one or more of the same or different halogens and 6 membered heteroaryl optionally substituted with one or more of the same or different halogens; and R a
- R 9 groups that may be used to substitute L 1 and L 2 include -OR , -C(O)OR , phenyl, halophenyl and 4-halophenyl, wherein R a is as previously defined for structural formula (I).
- L 1 and L 2 are each, independently of one another, selected from the group consisting of methano, ethano and propano, each of which may be optionally monosubstituted with an R 9 group, where R 9 is as previously defined above.
- R 9 is as previously defined above.
- specific R a groups that may be included in R 9 groups are selected from the group consisting of hydrogen, (C1-C6) alkyl, phenyl and benzyl.
- L and L are each a direct bond such that the 2,4-pyrimidinediamine compounds of the invention are compounds according to structural formula (la):
- R 2 , R 4 , R 5 , R 6 , L 1 and L 2 are as previously defined for their respective structures (I) and (la), with the proviso that R 2 is not 3,4,5-trimethoxyphenyl, 3,4,5-tri (C1-C6) alkoxyphenyl or
- R 21 , R 22 and R 23 are as defined for R 1 , R 2 and R 3 , respectively of U.S. Patent No. 6,235,746, the disclosure of which is incorporated by reference.
- R 21 is hydrogen, halo, straight-chain or branched (Cl- C6) alkyl optionally substituted with one or more of the same or different R 25 groups, hydroxyl, (C1-C6) alkoxy optionally substituted with one or more of the same or different phenyl or R 25 groups, thiol (-SH), (C1-C6) alkylthio optionally substituted with one or more of the same or different phenyl or R 25 groups, amino (-NH 2 ), -NHR 26 or -NR 26 R 26 ;
- R 22 and R 23 are each, independently of one another, a (C1-C6) straight-chain or branched alkyl optionally substituted with one or more of the same or different R 25 groups;
- R 25 is selected from the group consisting
- R 21 is methoxy optionally substituted with one or more of the same or different halo groups and/or R 22 and R 23 are each, independently of one another, a methyl or ethyl optionally substituted with one or more of the same or different halo groups.
- R 2 , R 4 , R 5 and L 2 are as previously described for their respective structures (I) and (la), L 1 is a direct bond and R is hydrogen, with the proviso that R 2 is not 3,4,5-trimethoxyphenyl, 3 ,4,5-tri (C 1 -C6) alkoxyphenyl or
- R , R and R are as defined above, in connection with the first embodiment.
- the 2,4-pyrimidinediamine compounds of structural formulae (I) and (la) exclude one or more of the following compounds:
- N2,N4-bis(2-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine R088815
- N2,N4-bisphenyl-5-fluoro-2,4-pyrimidinediamine R091880
- N2,N4-bis(3,4-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamme R067964
- N2,N4-bis(4-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine R0707153
- the compounds of structural formulae (I) and (la) exclude compounds according to the following structural formula (lb):
- R 24 is (C1-C6) alkyl; and R 21 , R 22 and R 23 are as previously defined in connection with the first embodiment.
- the compounds of structural formulae (I) and (la) exclude the compounds described in Examples 1-141 of U.S. Patent No. 6,235,746, the disclosure of which is incorporated herein by reference.
- the compounds of structural formulae (I) and (la) exclude compounds defined by formula (1) or formula 1(a) of this U.S. Patent No. 6,235,746 (see, e.g., the disclosure at Col. 1, line 48 through Col. 7, line 49 and Col. 8, lines 9-36, which is incorporated by reference).
- the compounds of structural formulae (I) and (la) exclude compounds in which R 5 is cyano or -C(O)NHR, where R is hydrogen or (C1-C6) alkyl, when R 2 is a substituted phenyl; R4 is a substituted or unsubstituted (C1-C6) alkyl, (C 3 -C 8 ) cycloalkyl, 3-8 membered cycloheteralkyl or 5-15 membered heteroaryl; and R is hydrogen.
- the compounds of structural formulae (I) and (la) exclude the compounds defined by formulae (I) and (X) of WO 02/04429 or any compound disclosed in WO 02/04429, the disclosure of which is incorporated herein by reference.
- R 5 is cyano or -C(O)NHR, where R is hydrogen or (Cl -C6) alkyl; and R 6 is hydrogen, then R 2 is other than a substituted phenyl group.
- the compounds of structural formulae (I) and (la) exclude compounds in which R 2 and R 4 are each independently a substituted or unsubstituted pyrrole or indole ring which is attached to the remainder of the molecule via its ring nitrogen atom.
- the compounds of structural formulae (I) and (la) exclude compounds defined by formulae (I) and (IV) of U.S. Patent No. 4,983,608 or any compound disclosed in U.S. Patent No. 4,983,608, the disclosure of which is incorporated herein by reference.
- R 2 and R 4 may be the same or different, and may vary broadly.
- R 2 and/or R 4 are optionally substituted rings, such as optionally substituted cycloalkyls, cycloheteroalkyls, aryls and heteroaryls, the ring may be attached to the remainder of the molecule through any available carbon or heteroatom.
- the optional substituents may be attached to any available carbon atoms and/or heteroatoms.
- R 2 and/or R 4 is an optionally substituted phenyl or an optionally substituted (C5-C15) aryl, subject to the provisos that (1) when R 6 is hydrogen, then R 2 is not 3,4,5-trimethoxyphenyl or 3,4,5-tri (C1-C6) alkoxyphenyl; (2) when R 2 is a 3,4,5-trisubstituted phenyl, then the substituents at the 3- and 4-positions are not simultaneously methoxy or (C1-C6) alkoxy; or (3) when R 6 is hydrogen and R 4 is (C1-C6) alkyl, (C 3 -C 8 ) cycloalkyl, 3-8 membered cycloheteroalkyl or 5-15 membered heteroaryl, then R 5 is other than cyano.
- R 2 is subject to the provisos described in connection with the first or second embodiments.
- the optionally substituted aryl or phenyl group may be attached to the remainder of the molecule through any available carbon atom.
- Specific examples of optionally substituted phenyls include phenyls that are optionally mono-, di- or tri-substi ⁇ uted with the same or different R groups, where R is as previously defined for structural formula (I) and subject to the above provisos.
- the R 8 substituent may be positioned at either the ortho, meta or para position.
- R 8 is preferably selected from the group consisting of (C1-C10) alkyl, (Cl- C10) branched alkyl, -OR a optionally substituted with one or more of the same or different R b groups, -O-C(O)OR a , -O-(CH 2 ) lake,-C(O)OR a , -C(O)OR a , -O-(CH 2 ) m -NR c R c , -O-C(O)NR c R c , -O-(CH 2 ) m -C(O)NR c R c , -O-C(NH)NR c R c , -O-(CH 2 ) m -C(NH)NR c R c and -NH-(CH 2 ), rule-NR C R C , where m, R and R c are as previously defined for structural formula (I).
- -NR C R C is a 5-6 membered heteroaryl which optionally includes one or more of the same or different additional heteroatoms.
- 5-6 membered heteroaryls include, but are not limited to, oxadiazolyl, triazolyl, thiazolyl, oxazolyl, tetrazolyl and isoxazolyl.
- -NR C R C is a 5-6 membered saturated cycloheteroalkyl ring which optionally includes one or more of the same or different heteroatoms.
- cycloheteroalkyls include, but are not limited to, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, piperidinyl, piperazinyl and morpholinyl.
- each R a is independently a (C1-C6) alkyl and/or each -NR C R° is -NHR a , where R a is a (C1-C6) alkyl.
- R 8 is -O-CH 2 -C(O)NHCH 3 .
- R 8 is -OH.
- the R 8 substituents may be positioned at any combination of positions.
- the R substituents may be positioned at the 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5-, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,5-, 2,4,6-, 2,5,6- or 3,4,5-positions.
- the substituents are positioned other than 3,4.
- they are positioned 3,4.
- the substituents are positioned other than 3,4,5 or, alternatively, no two of the substituents are positioned 3,4.
- the substituents are positioned 3,4,5.
- R 8 substituents in such di- and trisubstituted phenyls include the various R 8 substituents described above in connection with the ortho, meta and para substituted phenyls.
- R 8 substituents useful for substititutmg such di-and trisubstituted phenyls include (C1-C6) alkyl, (C1-C6) alkoxy, methoxy, halo, chloro,
- R 8 substituents are positioned 3,4 or 3,5.
- Specific examples of preferred di-substituted phenyl rings include 3-chloro-4-methoxy-phenyl, 3-methoxy-4-chlorophenyl, 3 -chloro-4-trifluoromethoxy-phenyl, 3 -trifluoromethoxy-4-chloro-phenyl, 3,4-dichloro-phenyl, 3,4-dimethoxyphenyl and 3,5-dimethoxyphenyl, with the provisos that: (1) when R 4 is one of the above-identified phenyls, and R 5 and R 6 are each hydrogen, then R 2 is not 3,4,5-tri(Cl-C6)alkoxyphenyl or 3,4,5-trimethoxyphenyl; (2) when R 2 is 3,4-dimethoxy
- the trisubstituted phenyl has the formula:
- R 31 is methyl or (C1-C6) alkyl
- R 32 is hydrogen, methyl or (C1-C6) alkyl
- R 33 is a halo group.
- R 2 and/or R is an optionally substituted heteroaryl.
- Typical heteroaryl groups according to this thirteenth embodiment comprise from 5 to 15, and more typically from 5 to 11 ring atoms, and include one, two, three or four of the same or different heteratoms or heteroatomic groups selected from the group consisting of N, NH, O, S, S(O) and S(O) 2 .
- the optionally substituted heteroaryl may be attached to its respective C2 or C4 nitrogen atom or linker L 1 or L 2 through any available carbon atom or heteroatom, but is typically attached via a carbon atom.
- the optional substituents may be the same or different, and may be attached to any available carbon atom or heteroatom.
- R 5 is other than bromo, nitro, trifluoromethyl, cyano or -C(O)NHR, where R is hydrogen or (C1-C6) alkyl.
- R 2 and R 4 are each a substituted or unsubstituted pyrrole or indole, then the ring is attached to the remainder of the molecule via a ring carbon atom.
- the heteroaryl is unsubstituted or substituted with from one to four of the same or different R 8 groups, where R 8 is as previously defined for structural formula (I).
- R 8 is as previously defined for structural formula (I).
- Specific examples of such optionally substituted heteroaryls include, but are not limited to, the following heteroaryl groups:
- p is an integer from one to three; each — independently represents a single bond or a double bond;
- R 35 is hydrogen or R 8 , where R 8 is as previously defined for structural formula (I);
- X is selected from the group consisting of CH, N and N-O; each Y is independently selected from the group consisting of O, S and NH; each Y 1 is independently selected from the group consisting of O, S, SO, SO 2 , SONR 36 , NH and NR 37 ; each Y 2 is independently selected from the group consisting of CH, CH 2 , O, S, N, NH and NR 37 ;
- R 36 is hydrogen or alkyl
- R is selected from the group consisting of hydrogen and a progroup, preferably hydrogen or a progroup selected from the group consisting of aryl, arylalkyl, heteroaryl, R a , R b -CR a R b -O-C(O)R 8 , -CR a R b -O-PO(OR 8 ) 2 , -CH 2 -O-PO(OR 8 ) 2 , -CH 2 -PO(OR 8 ) 2 , -C(O)-CR a R b -N(CH 3 ) 2 , -CR a R b -O-C(O)-CR a R b -N(CH 3 ) 2 , -C(O)R 8 , -C(O)CF 3 and -C(O)-NR 8 -C(O)R 8 ;
- A is selected from the group consisting of O, NH and NR 38 ;
- R 38 is selected from the group consisting of alkyl and aryl;
- R 9 , R 10 , R 11 and R 12 are each, independently of one another, selected from the group consisting of alkyl, alkoxy, halogen, haloalkoxy, aminoalkyl and hydroxyalkyl, or, alternatively, R 9 and R 10 and/or R 11 and R 12 are taken together form a ketal;
- each Z is selected from the group consisting of hydroxyl, alkoxy, aryloxy, ester, carbamate and sulfonyl;
- Q is selected from the group consisting of -OH, OR 8 , -NR C R C ,
- R 39 and R 40 are each, independently of one another, selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl;arylalkyl and HR ; and R a , R and R c are as previously defined for structural formula (I). Preferred
- R b substitutents for Q are selected from -C(O)OR 8 , -O-C(O)R 8 , -O-P(O)(OR 8 ) 2 and
- each R 8 is independently selected from the group consisting of R d , -NR C R C , -(CH 2 ), puzzle-NR C R C ,
- R and/or R c is selected from the group consisting of R and (C3-C8) cycloalkyl optionally substituted with one or more of the same or different hydroxyl, amino or carboxyl groups.
- each R 35 is a hydrogen atom, a (C1-C6) carbon chain, including methyl, ethyl, isopropyl, a cycloalkyl group, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, a
- the aromatic ring connectivity is either at the 5 or 6 position. It should be understood that either R 2 or R 4 can utilize the heteroaryl groups discussed throughout this specification.
- R 2 and R 4 are each, independently of one another, an optionally substituted phenyl, aryl or heteroaryl, with the provisos that: (1) when L 1 is a direct bond and R 6 and optionally R 5 is hydrogen, then R 2 is other than 3,4,5-trimethoxyphenyl or 3,4,5-tri(Cl-C6) alkoxyphenyl; (2) when L 1 and L 2 are each a direct bond, R 6 is hydrogen and R 5 is halo, then R 2 and R 4 are not each simultaneously 3,4,5-trimethoxyphenyl or 3,4,5-tri(Cl-C6) alkoxyphenyl; (3) when R 4 is 3-methoxyphenyl or 3-(Cl-C6) alkoxyphenyl and R 2 is a 3,4,5-trisubstituted phenyl, the substituents positioned at the 3 and 4 positions are not both simultaneously methoxy or (C1-C6) alkoxy; (4)
- R 2 and R 4 substituents may be the same or different.
- Specific optionally substituted phenyl, aryl and/or heteroaryls include those illustrated above in connection with the twelfth and thirteenth embodiments.
- R 6 is hydrogen and R 5 is an electronegative group.
- electronegative groups are atoms or groups of atoms that have a relatively great tendency to attract electrons to themselves.
- electronegative groups according to this fourteenth embodiment include, but are not limited to, -CN, -NC, -NO 2 , halo, bromo, chloro, fluoro, (C1-C3) haloalkyl, (C1-C3) perhaloalkyl, (C1-C3) fluoroalkyl, (C1-C3) perfluoroalkyl, -CF 3 , (C1-C3) haloalkoxy, (C1-C3) perhaloalkoxy, (C1-C3) fluoroalkoxy, (C1-C3) perfluoroalkoxy, -OCF 3 , -C(O)R a , -C(O)OR a , -C(O)CF 3 and -C(O)OCF 3 .
- the electronegative group is a halogen-containing electronegative group, such as -OCF 3 , -CF 3 , bromo, chloro or fluoro.
- R 5 is fluoro, subject to the proviso that the the compound is not any compound according to the third embodiment.
- the compounds of structural formulae (I) and (la) are compounds according to structural formula (lb):
- R 11 , R 12 , R 13 and R 14 are each, independently of one another, selected from the group consisting of hydrogen, hydroxy, (C1-C6) alkoxy and — NR C R C ; and R 5 , R 6 and R c are as previously defined for structural formula (I), with the proviso that when R 13 , R 5 and R 6 are each hydrogen, then R 11 and R 12 are not simultaneously methoxy, (C1-C6) alkoxy or (C1-C6) haloalkoxy
- the compounds of structural formulae (I) and (la) are compounds according to structural formula (Ic):
- R 4 is selected from the group consisting of 5-10 membered heteroaryl and 3 -hydroxyphenyl
- R 5 is F or -CF 3 ;
- R 8 is -O(CH 2 ) m -R b , where m and R b are as previously defined for structural formula (I).
- R 8 is -O-CH 2 -C(O)NH-CH 3 and/or R 4 is a heteroaryl according to the thirteenth embodiment.
- the compounds of structural formulae (I) and (la) include any compound selected from TABLE 1 that inhibits an Fc receptor signal transduction cascade, a Syk kinase activity, a Syk-kinase dependent receptor signal transduction cascade orcell degranulation as measured in an in vitro assay, optionally subject to the proviso that the compound is not a compound excluded by the above- described third embodiment and/or other embodiments.
- such compounds have an IC50 of about 20 ⁇ M or less as measured in an in vitro degranulation assay, such as one of the degranulation assays described in the Examples section.
- the compounds of structural formulae (I) and (la) include any compound selected from TABLE 1 that inhibits the Fc ⁇ RI or FceRI receptor cascade with an IC50 of about 20 ⁇ M or less as measured in an in vitro assay, such as one of the in vitro assays provided in the Examples section, optionally subject to the proviso that the compound is not a compound excluded by the above-described third embodiment and/or other embodiments.
- the compounds of structural formulae (la) are those
- R 4 , R 8 , R a , R b , R c , R d are as described above, R 5 is a fluorine atom; R 6 is a hydrogen atom and each R 21 is independently a halogen atoms or an alkyl optionally substituted with one or more of the same or different halo groups, R 22 and R 23 are each, independently of one another, a hydrogen atom, methyl or ethyl optionally substituted with one or more of the same or different halo groups, each m is independently an integer from 1 to 3, and each n is independently an integer from 0 to 3.
- the compounds of structural formulae (la) are those
- R is R and R .10 are as defined above and further include, each independently a hydrogen atom, and R is a phenyl group, substituted with
- R is a phenyl group
- one or more of R is selected from a halogen and an alkoxy group.
- the phenyl group is di or tri substituted with one or more of the same R 8 groups.
- R 4 is and R 2 is a phenyl group, substituted with one or more of the same R 8 groups.
- one or more of R 8 is selected from a halogen and an alkoxy group.
- the phenyl group is di or tri substituted with one or more of the same R 8 groups.
- the compounds of structural formulae (la) are those wherem R 4 is a phenyl group substituted with one or more of the same R 8 groups, wherein
- R 35 is as defined above.
- the R 4 phenyl group is di or tri substituted with the the same or different halgoen atoms.
- R 4 is a monosubstituted phenyl group with a halogen atom.
- R 35 is a hydroxyalkyl group. In certain aspects, the hydroxyalkyl group can be further functionalized into an ester group, carbamate, etc.
- R is wherein R is as defined above and R is a phenyl group substituted with one or more of the same R groups.
- R is a hydrogen atom or an alkyl group.
- the R 2 phenyl group is di or tri substituted with the same or different R groups, and in particular, halogen atoms.
- R is wherein R 35 is as defined above and R 2 is
- R 9 and R 10 are defined as above and further include, each independently a hydrogen atom.
- R 35 is a hydrogen atom or an alkyl group, e.g., methyl and R 9 and R 10 are alkyl groups, e.g., methyl groups.
- the compounds of structural formulae (la) are those wherein R 4 is a disubstituted phenyl group, substituted with the same or different R 8
- R 35 is as defined above.
- the phenyl group is substituted with a halogen atom and an alkyoxy group, e.g. a methoxy group.
- R 35 is a hydrogen atom, an alkyl group, e.g., a methyl group, or a hydroxyalkyl group.
- the hydroxyalkyl group can be further functionalized into an ester group, carbamate, etc.
- R c are as defined above and R 2 is a phenyl group that is substituted with one or more of the same R 8 groups.
- R c is a hydrogen atom or an alkyl group.
- the R 2 phenyl group is di or tri substituted with the same or different R 8
- R 4 is wherein Y , Y and each R independently, are defined
- R is wherein R >35 is as defined above.
- Y 1 is oxygen
- Y 2 is NH
- one or more of R 35 or the R 4 moiety is an alkyl group, and in particular, a methyl group.
- two R 35 's of the R 4 moiety form a gem dialkyl moiety, in particular, a gem dimethyl moiety adjacent to the NH depicted as
- R >35 is a hydrogen atom or an alkyl group, and in particular, a methyl group.
- R is wherein R 9 and R 10 are as defined above or a substituted phenyl group.
- the phenyl group is di or tri substituted with one or more of the same R 8 groups.
- the phenyl group can be di or tri substituted with one or more halogen atoms that can be the same or different.
- R 2 in the twenty nineth embodiment is
- R >35 is as defined above.
- R ,35 ofR is not a methyl group.
- R is or
- R 5 is a halogen atom, such as fluorine
- R 6 is a hydrogen atom
- the 2,4-pyrimidinediamine compounds described herein may include functional groups that can be masked with progroups to create prodrugs. Such prodrugs are usually, but need not be, pharmacologically inactive until converted into their active drug form. Indeed, many of the active 2,4-pyrimidinediamine compounds described in TABLE 1, infra, include promoieties that are hydrolyzable or otherwise cleavable under conditions of use. For example, ester groups commonly undergo acid-catalyzed hydrolysis to yield the parent carboxylic acid when exposed to the acidic conditions of the stomach, or base-catalyzed hydrolysis when exposed to the basic conditions of the intestine or blood.
- 2,4- pyrimidinediamines that include ester moieties may be considered prodrugs of their corresponding carboxylic acid, regardless of whether the ester form is pharmacologically active.
- ester form is pharmacologically active.
- numerous ester-containing 2,4-pyrimidinediamines of the invention are active in their ester, "prodrug" form.
- any available functional moiety may be masked with a progroup to yield a prodrug.
- Functional groups within the 2,4-pyrimidinediamine compounds that may be masked with progroups for inclusion in a promoiety include, but are not limited to, amines (primary and secondary), hydroxyls, sulfanyls (thiols), carboxyls, etc.
- progroups suitable for masking such functional groups to yield promoieties that are cleavable under the desired conditions of use are known in the art. All of these progroups, alone or in combinations, may be included in the prodrugs of the invention.
- the prodrugs of the invention are compounds according to structural formula (I) in which R c and R may be, in addition to their previously-defined alternatives, a progroup. Replacing the hydrogens attached to N2 and N4 in the 2,4-pyrimidinediamines of structural formula (I) with substituents adversely effects the activity of the compounds.
- these nitrogens may be included in promoieties that, under conditions of use, cleave to yield 2,4-pyrimidinediamines according to structural formula (I).
- the prodrugs of the invention are compounds according to structural formula (II):
- R 2 , R 4 , R 5 , R 6 , L 1 and L 2 are as previously defined for structural formula (I); and R 2b and R 4b are each, independently of one another, a progroup.
- Specific examples of progroups according to this embodiment of the invention include, but are not limited to,
- the various substituents may be as described for the various first through twentieth embodiments previously described for the compounds of structural formulae (I) and (la), or combinations of such embodiments.
- the compounds and prodrugs of the invention may exhibit the phenomena of tautomerism, conformational isomerism, geometric isomerism and/or optical isomerism.
- the compounds and prodrugs of the invention may include one or more chiral centers and/or double bonds and as a consequence may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers and diasteromers and mixtures thereof, such as racemic mixtures.
- the compounds and prodrugs of the invention may exist in several tautomeric forms, including the enol form, the keto form and mixtures thereof.
- the compounds and/or prodrugs of the invention may be identified by either their chemical structure or their chemical name. When the chemical structure and the chemical name conflict, the chemical structure is determinative of the identity of the specific compound.
- the 2,4-pyrimidinediamine compounds and prodrugs of the invention may be in the form of salts.
- Such salts include salts suitable for pharmaceutical uses ("pharmaceutically-acceptable salts"), salts suitable for veterinary uses, etc.
- Such salts may be derived from acids or bases, as is well-known in the art.
- the salt is a pharmaceutically acceptable salt.
- pharmaceutically acceptable salts are those salts that retain substantially one or more of the desired pharmacological activities of the parent compound and which are suitable for administration to humans.
- Pharmaceutically acceptable salts include acid addition salts formed with inorganic acids or organic acids.
- Inorganic acids suitable for forming pharmaceutically acceptable acid addition salts include, by way of example and not limitation, hydrohalide acids (e.g., hydrochloric acid, hydrobromic acid, hydriodic, etc.), sulfuric acid, nitric acid, phosphoric acid, and the like.
- Organic acids suitable for forming pharmaceutically acceptable acid addition salts include, by way of example and not limitation, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, oxalic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, palmitic acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, alkylsulfonic acids (e.g., methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, etc.), arylsulfonic acids (e.g., benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenes
- Pharmaceutically acceptable salts also include salts formed when an acidic proton present in the parent compound is either replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth metal ion or an aluminum ion), an ammonium ion or coordinates with an organic base (e.g., ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, mo holine, piperidine, dimethylamine, diethylamine, etc.).
- a metal ion e.g., an alkali metal ion, an alkaline earth metal ion or an aluminum ion
- an ammonium ion or coordinates with an organic base e.g., ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, mo holine, piperidine, dimethylamine, diethylamine, etc.
- the 2,4-pyrimidinediamine compounds and of the invention, as well as the salts thereof, may also be in the form of hydrates, solvates and N-oxides, as are well-known in the art. 6.3 Methods of Synthesis
- the compounds and prodrugs of the invention may be synthesized via a variety of different synthetic routes using commercially available starting materials and/or starting materials prepared by conventional synthetic methods. Suitable exemplary methods that may be routinely adapted to synthesize the 2,4-pyrimidinediamine compounds and prodrugs of the invention are found in U.S. Patent No. 5,958,935, the disclosure of which is incorporated herein by reference. Specific examples describing the synthesis of numerous compounds and prodrugs of the invention, as well as intermediates therefor, are provided in the Examples section. All of the compounds of structural formulae (I), (la) and (II) may be prepared by routine adaptation of these methods.
- R 2 , R , R , R , L and L 2 are as previously defined for structural formula (I), X is a halogen (e.g., F, Cl, Br or I) and Y and Y' are each, independently of one another, selected from the group consisting of O and S.
- X is a halogen (e.g., F, Cl, Br or I)
- Y and Y' are each, independently of one another, selected from the group consisting of O and S.
- uracil or thiouracil 2 is dihalogenated at the 2- and 4-positions using standard halogenating agent POX 3 (or other standard halogenating agent) under standard conditions to yield 2,4-bishalo pyrimidine 4.
- POX 3 or other standard halogenating agent
- the C4 halide is more reactive towards nucleophiles, as illustrated in the Scheme.
- the identity of the R 5 substituent may alter this reactivity.
- R 5 is trifluoromethyl
- a 50:50 mixture of 4N-substituted-4-pyrimidineamine 8 and the corresponding 2N-substituted-2- pyrimidineamine is obtained.
- the regioselectivity of the reaction can be controlled by adjusting the solvent and other synthetic conditions (such as temperature), as is well-known in the art.
- the reactions depicted in Scheme (I) may proceed more quickly when the reaction mixtures are heated via microwave. When heating in this fashion, the following conditions may be used: heat to 175°C in ethanol for 5-20 min. in a Smith Reactor (Personal Chemistry) in a sealed tube (at 20 bar pressure).
- the uracil or thiouracil 2 starting materials may be purchased from commercial sources or prepared using standard techniques of organic chemistry.
- Commercially available uracils and thiouracils that can be used as starting materials in Scheme (I) include, by way of example and not limitation, uracil (Aldrich #13,078-8; CAS Registry 66-22-8); 2- thio-uracil (Aldrich #11,558-4; CAS Registry 141-90-2); 2,4-dithiouracil (Aldrich #15,846- 1; CAS Registry 2001-93-6); 5-acetouracil (Chem. Sources Int'l 2000; CAS Registry 6214- 65-9); 5-azidouracil; 5-aminouracil (Aldrich #85,528-6; CAS Registry 932-52-5);
- 5-bromouracil (Aldrich #85,247-3; CAS Registry 51-20-7); 5-(trans-2-bromovinyl)-uracil (Aldrich #45,744-2; CAS Registry 69304-49-0); 5-(trans-2-chlorovinyl)-uracil (CAS Registry 81751-48-2); 5-(trans-2-carboxyvinyl)-uracil; uracil-5-carboxylic acid (2,4-dihydroxypyrimidine-5-carboxylic acid hydrate; Aldrich #27,770-3; CAS Registry 23945-44-0); 5-chlorouracil (Aldrich #22,458-8; CAS Registry 1820-81-1); 5-cyanouracil (Chem.
- Amines 6 and 10 may be purchased from commercial sources or, alternatively, may be synthesized utilizing standard techniques. For example, suitable amines may be synthesized from nitro precursors using standard chemistry. Specific exemplary reactions are provided in the Examples section. See also Nogel, 1989, Practical Organic Chemistry, Addison Wesley Longman, Ltd. and John Wiley & Sons, Inc.
- amines 6 and 10 and/or substituents R 5 and or R 6 on uracil or thiouracil 2 may include functional groups that require protection during synthesis.
- the exact identity of any protecting group(s) used will depend upon the identity of the functional group being protected, and will be apparent to these of skill in the art.
- Guidance for selecting appropriate protecting groups, as well as synthetic strategies for their attachment and removal, may be found, for example, in Greene & Wuts, Protective Groups in Organic Synthesis, 3d Edition, John Wiley & Sons, Inc., New York (1999) and the references cited therein (hereinafter "Greene & Wuts").
- Scheme (I) utilizing 5-fluorouracil (Aldrich #32,937-1) as a starting material is illustrated in Scheme (la), below:
- R 2 , R 4 , L 1 and L 2 are as previously defined for Scheme (I).
- 5-fluorouracil 3 is halogenated with POCl 3 to yield 2,4-dichloro- 5-fluoropyrimidine 5, which is then reacted with excess amine 6 or 10 to yield N2,N4-bis substituted 5-fluoro-2,4-pyrimidinediamine 11 or 13, respectively.
- asymmetric 2N,4N-disubstituted-5-fluoro-2,4-pyrimidinediamine 9 may be obtained by reacting 2,4-dichloro-5-fluoropyrimidine 5 with one equivalent of amine 10 (to yield 2- chloro-N4-substituted-5-fluoro-4-pyrimidineamine 7) followed by one or more equivalents of amine 6.
- 2,4-pyrimidinediamine compounds of the invention may be synthesized from substituted or unsubstituted cytosines as illustrated in Schemes (Ila) and (lib), below: Scheme (lla)
- Protected cytosine 22 is halogenated at the C2 position using a standard halogenation reagent under standard conditions to yield 2-chloro-4 ⁇ -protected-4-pyrimidineamine 24. Reaction with amine 6 followed by deprotection of the C4 exocyclic amine and reaction with amine 10 yields a 2,4-pyrimidinediamine according to structural formula (1).
- cytosine 20 may be reacted with amine 10 or protected amine 21 to yield N4-substituted cytosine 23 or 27, respectively.
- substituted cytosines may then be halogenated as previously described, deprotected (in the case of N4-substituted cytosine 27) and reacted with amine 6 to yield a 2,4-pyrimidinediamine according to structural formula (I).
- cytosines that may be used as starting materials in Schemes (Ha) and (lib) include, but are not limited to, cytosine (Aldrich #14,201-8; CAS Registry 71-30-7); N 4 -acetylcytosine (Aldrich #37,791-0; CAS Registry 14631-20-0); 5-fluorocytosine (Aldrich #27,159-4; CAS Registry 2022-85-7); and 5-(trifluoromethyl)- cytosine.
- cytosines useful as starting materials in Schemes (lla) are available from General Intermediates of Canada, Inc., Edmonton, Alberta, CA (www, generalintermediates.com and/or Interchim, France (www.interchim.com), or may be prepared using standard techniques. Myriad textbook references teaching suitable synthetic methods are provided infra.
- 2,4-pyrimidinediamine compounds of the invention may be synthesized from substituted or unsubstituted 2-amino-4-pyrimidinols as illustrated in Scheme (III), below: Scheme (III)
- Suitable commercially-available 2-amino-4-pyrimidinols 30 that can be used as starting materials in Scheme (III) include, but are not limited to, 2-amino-6-chloro-4-pyrimidinol hydrate (Aldrich #A4702-8; CAS Registry 00000-00-0) and 2-amino-6-hydroxy-4-pyrimidinol (Aldrich #A5040- 1 ; CAS Registry 56-09-7).
- Other 2-amino-4-pyrimidinols 30 useful as starting materials in Scheme (III) are available from General Intermediates of Canada, Inc., Edmonton, Alberta, CA
- 2,4-pyrimidinediamine compounds of the invention may be prepared from substituted or unsubstituted 4-amino-2-pyrimidinols as illustrated in Scheme (IN), below:
- R 2 , R 4 , R 5 , R 6 , L 1 and L 2 are as previously defined for Scheme (I) and Z represents a leaving group.
- Z represents a leaving group.
- the C2-hydroxyl of 4-amino-2-pyrimidinol 40 is more reactive towards nucleophiles than the C4-amino such that reaction with amine 6 yields ⁇ 2-substituted-2,4-pyrimidinediamine 42.
- Subsequent reaction with compound 44, which includes a good leaving group Z, or amine 10 yields a 2,4-pyrimidinediamine according to structural formula (I).
- Compound 44 may include virtually any leaving group that can be displaced by the C4-arnino of N2-substituted-2,4-pyrimidmediamine 42.
- Suitable leaving groups Z include, but are not limited to, halogens, methanesulfonyloxy (mesyloxy; "OMs"), trifluoromethanesulfonyloxy ("OTf ) and ⁇ -toluenesulfonyloxy (tosyloxy; "OTs”), benzene sulfonyloxy ("besylate”) and metanitro benzene sulfonyloxy ("nosylate”).
- halogens methanesulfonyloxy (mesyloxy; "OMs”), trifluoromethanesulfonyloxy ("OTf ) and ⁇ -toluenesulfonyloxy (tosyloxy; "OTs”), benzene sulfonyloxy ("besy
- the 2,4-pyrimidinediamine compounds of the invention can be prepared from 2-chloro-4-aminopyrimidines or 2-amino-4-chloropyrimidines as illustrated in Scheme (V), below: Scheme (V)
- V are commercially available, including by way of example and not limitation, 2-amino-4,6-dichloropyrimidine (Aldrich #A4860-1; CAS Registry 56-05-3); 2-amino-4-chloro-6-methoxy-pyrimidine (Aldrich #51,864-6; CAS Registry 5734-64-5); 2-amino-4-chloro-6-methylpyrimidine (Aldrich #12,288-2; CAS Registry 5600-21-5); and 2-amino-4-chloro-6-methylthiopyrimidine (Aldrich #A4600-5; CAS Registry 1005-38-5).
- 2-amino-4,6-dichloropyrimidine Aldrich #A4860-1; CAS Registry 56-05-3
- 2-amino-4-chloro-6-methoxy-pyrimidine Aldrich #51,864-6; CAS Registry 5734-64-5
- 2-amino-4-chloro-6-methylpyrimidine Aldrich #12,288-2;
- R 5 and R 6 are as previously defined for structural formula (I).
- dicarbonyl 53 is reacted with guanidine to yield 2-pyrimidineamine 51.
- Reaction with peracids like m-chloroperbenzoic acid, trifluoroperacetic acid or urea hydrogen peroxide complex yields N-oxide 55, which is then halogenated to give 4-chloro- 2-pyrimidineamine 50.
- the corresponding 4-halo-2-pyrimidineamines may be obtained by using suitable halogenation reagents.
- the 2,4-pyrimidinediamine compounds of the invention can be prepared from substituted or unsubstituted uridines as illustrated in Scheme (VI), below:
- R 2 , R 4 , R 5 , R 6 , L 1 , L 2 and X are as previously defined for Scheme (I) and the superscript PG represents a protecting group, as discussed in connection with Scheme (lib).
- uridine 60 has a C4 reactive center such that reaction with amine 10 or protected amine 21 yields N4-substituted cytidine 62 or 64, respectively.
- N4-substituted 62 or 64 Acid-catalyzed deprotection of N4-substituted 62 or 64 (when "PG” represents an acid-labile protecting group) yields N4-substituted cytosine 28, which may be subsequently halogenated at the C2-position and reacted with amine 6 to yield a 2,4-pyrimidinediamine according to structural formula (I).
- uridines and cytidines useful as starting materials in Schemes (VI) and (VII) are known in the art, and include, by way of example and not limitation, 5-trifluoromethyl-2'-deoxycytidine (Chem. Sources #ABCR F07669; CAS Registry 66,384- 66-5); 5-bromouridine (Chem.
- 2,4-pyrimidinediamine compounds of the invention can also be synthesized from substituted pyrimidines, such as chloro-substituted pyrimidines, as illustrated in Schemes (VIII) and (IX), below:
- N2,N4-bis-substituted-2,4-pyrimidinediamines can be prepared in a manner analogous to Scheme (VIII) by employing 2,4-dichloro-5-methylpyrimidine or 2,4-dichloro- pyrimidine as starting materials. In this instance, the mono-substituted pyrimidineamine corresponding to compound 81 is not obtained. Instead, the reaction proceeds to yield the N2,N4-bis-substituted-2,4-pyrimidinediamine directly. Referring to Scheme (IX), 2,4,5,6-tetrachloropyrimidine 90 (Aldrich #24,671 -9;
- N2,N4-bis-substituted-5,6,-dichloro-2,4-pyrimidinediamine 92 may be further reacted at the C6 halide with, for example a nucleophilic agent 94 to yield compound 95.
- compound 92 can be converted into N2,N4-bis-subsituted-5- chloro-6-aryl-2,4-pyrimidinediamine 97 via a Suzuki reaction.
- 2,4-Pyrimidinediamine 95 may be converted to 2,4-pyrimidinediamine 99 by reaction with Bn 3 SnH.
- 2,4-pyrimidinediamines according to the invention may also be utilized as starting materials and/or intermediates to synthesize additional 2,4-pyrimidinediamine compounds of the invention.
- Scheme (X) A specific example is illustrated in Scheme (X), below:
- R 4 , R 5 , R 6 , L 2 and R a are as previously defined for structural formula (I). Each R a is independently an R , and may be the same or different from the illustrated R a .
- carboxylic acid or ester 100 may be converted to amide 104 by reaction with amine 102.
- R a may be the same or different than R a of acid or ester 100.
- carbonate ester 106 may be converted to carbamate 108.
- R 4 , R 5 , R 6 , L 2 and R c are as previously defined for structural formula (I).
- amide 110 or 116 may be converted to amine 114 or 118, respectively, by borane reduction with borane methylsulfide complex 112.
- Other suitable reactions for synthesizing 2,4-pyrimidinediamine compounds from 2,4-pyrimidinediamine starting materials will be apparent to those of skill in the art.
- substituents R 2 , R 4 , R 5 , R 6 , L 1 and/or L 2 may include functional groups requiring protection.
- protecting group used will depend upon, among other things, the identity of the functional group being protected and the reaction conditions used in the particular synthetic scheme, and will be apparent to those of skill in the art. Guidance for selecting protecting groups and chemistries for their attachment and removal suitable for a particular application can be found, for example, in Greene & Wuts, supra.
- Prodrugs according to structural formula (II) may be prepared by routine modification of the above-described methods.
- such prodrugs may be prepared by reacting a suitably protected 2,4-pyrimidinediamine of structural formula (I) with a suitable progroup.
- Conditions for carrying out such reactions and for deprotecting the product to yield a prodrug of formula (II) are well-known.
- Active 2,4-pyrimidinediamine compounds of the invention inhibit Fc receptor signalling cascades that lead to, among other things, degranulation of cells.
- the compounds inhibit the FceRI and/or Fc ⁇ RI signal cascades that lead to degranulation of immune cells such as durophil, eosinophil, mast and/or basophil cells. Both mast and basophil cells play a central role in allergen-induced disorders, including, for example, allergic rhinitis and asthma.
- allergen-specific IgE antibodies are synthesized by B-cells activated by IL-4 (or IL-13) and other messengers to switch to IgE class specific antibody synthesis. These allergen-specific IgEs bind to the high affinity FceRI.
- the Fc ⁇ Rl -bound IgEs Upon binding of antigen, the Fc ⁇ Rl -bound IgEs are cross-linked and the IgE receptor signal transduction pathway is activated, which leads to degranulation of the cells and consequent release and/or synthesis of a host of chemical mediators, including histamine, proteases (e.g., tryptase and chymase), lipid mediators such as leukotrienes (e.g., LTC4), platelet-activating factor (PAF) and prostaglandins (e.g., PGD2) and a series of cytokines, including TNF- ⁇ , IL-4, IL-13, IL-5, IL-6, IL-8, GMCSF, VEGF and TGF- ⁇ .
- chemical mediators including histamine, proteases (e.g., tryptase and chymase), lipid mediators such as leukotrienes (e.g., LTC4), platelet
- the Fc ⁇ RI is a heterotetrameric receptor composed of an IgE-binding alpha-subunit, a beta subunit, and two gamma subunits (gamma homodimer).
- Cross-linking of FceRI-bound IgE by multivalent binding agents induces the rapid association and activation of the Src-related kinase Lyn.
- Lyn phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMS) on the intracellular beta and gamma subunits, which leads to the recruitment of additional Lyn to the beta subunit and Syk kinase to the gamma homodimer.
- ITAMS immunoreceptor tyrosine-based activation motifs
- PLC-gamma receptor-associated kinases
- Activated PLC-gamma initiates pathways that lead to protein kinase C activation and Ca 2+ mobilization, both of which are required for degranulation.
- Fc ⁇ Rl cross-linking also activates the three major classes of mitogen activated protein (MAP) kinases, i.e. ERKl/2, JNKl/2, and p38. Activation of these pathways is important in the transcriptional regulation of proinflammatory mediators, such as TNF- ⁇ and IL-6, as well as the lipid mediator leukotriene CA (LTC4).
- MAP mitogen activated protein
- the Fc ⁇ RI signaling cascade is believed to share some common elements with the FceRI signaling cascade.
- the Fc ⁇ RI includes a gamma homodimer that is phosphorylated and recruits Syk, and like FceRI, activation of the Fc ⁇ RI signaling cascade leads to, among other things, degranulation.
- Other Fc receptors that share the gamma homodimer, and which can be regulated by the active 2,4-pyrimidinediamine compounds include, but are not limited to, FcoRI and Fc ⁇ RIII.
- the ability of the 2,4-pyrimidinediamine compounds of the invention to inhibit Fc receptor signaling cascades may be simply determined or confirmed in in vitro assays. Suitable assays for confirming inhition of FceRI-mediated degranulation are provided in the Examples section.
- cells capable of undergoing FceRI-mediated degranulation such as mast or basophil cells, are first grown in the presence of IL-4, Stem Cell Factor (SCF), IL-6 and IgE to increase expression of the FceRI, exposed to a 2,4- pyrimidinediamine test compound of the invention and stimulated with anti-IgE antibodies (or, alternatively, an IgE-specific allergen).
- SCF Stem Cell Factor
- the amount of a chemical mediator or other chemical agent released and/or synthesized as a consequence of activating the FceRI signaling cascade may be quantified using standard techniques and compared to the amount of the mediator or agent released from control cells (i.e., cells that are stimulated but that are not exposed to test compound).
- the concentration of test compound that yields a 50% reduction in the quantity of the mediator or agent measured as compared to control cells is the IC 50 of the test compound.
- the origin of the mast or basophil cells used in the assay will depend, in part, on the desired use for the compounds and will be apparent to those of skill in the art.
- mast or basophil cells are human or other animal which constitutes an accepted or known clinical model for the particular disease.
- the mast or basophil cells may be derived from a wide variety of animal sources, ranging from, for example, lower mammals such as mice and rats, to dogs, sheep and other mammals commonly employed in clinical testing, to higher mammals such as monkeys, chimpanzees and apes, to humans.
- cells suitable for carrying out the in vitro assays include, but are not limited to, rodent or human basophil cells, rat basophil leukemia cell lines, primary mouse mast cells (such as bone marrow-derived mouse mast cells “BMMC”) and primary human mast cells isolated from cord blood (“CHMC”) or other tissues such as lung.
- BMMC bone marrow-derived mouse mast cells
- CHMC primary human mast cells isolated from cord blood
- Methods for isolating and culturing these cell types are well-known or are provided in the Examples section (see, e.g., Demo et al, 1999, Cytometry 36(4):340-348 and copending application Serial No. 10/053,355, filed November 8, 2001, the disclosures of which are incorporated herein by reference).
- the mediator or agent quantified is not critical. The only requirement is that it be a mediator or agent released and/or synthesized as a consequence of initiating or activating the Fc receptor signaling cascade. For example, referring to FIG. 1, activation of the FceRI signaling cascade in mast and/or basophil cells leads to numerous downstream events. For example, activation of the FceRI signal cascade leads to the immediate release (i.e., within 1-3 min. following receptor activation) of a variety of preformed chemical mediators and agents via degranulation.
- the mediator or agent quantified may be specific to granules (i.e., present in granules but not in the cell cytoplasm generally).
- granule-specific mediators or agents that can be quantified to determine and/or confirm the activity of a 2,4- pyrimidinediamine compound of the invention include, but are not limited to, granule- specific enzymes such as hexosaminidase and tryptase and granule-specific components such as histamine and serotonin. Assays for quantifying such factors are well-known, and in many instances are commercially available.
- tryptase and/or hexosaminidase release may be quantified by incubating the cells with cleavable substrates that fluoresce upon cleavage and quantifying the amount of fluorescence produced using conventional techniques.
- cleavable fluorogenic substrates are commercially available.
- the fluorogenic substrate 4- methylumbelliferyl-N-acetyl- ⁇ -D-glucosaminide (Sigma, St. Louis, MO, Catalog #69585) can be used to quantify the amount of hexosaminidase released. Histamine release may be quantified using a commercially available enzyme-linked immunosorbent assay (ELISA) such as Immunotech histamine ELISA assay #IM2015 (Beckman-Coulter, Inc.).
- ELISA enzyme-linked immunosorbent assay
- the 2,4- pyrimidinediamine compounds of the invention may also be assessed for activity by quantifying the amount of one or more of these mediators released and/or synthesized by activated cells. Unlike the granule-specific components discussed above, these "late stage" mediators are not released immediately following activation of the FceRI signaling cascade.
- the amount of a particular late stage mediator released may be quantified using any standard technique.
- the amount(s) may be quantified using ELISA assays.
- ELISA assay kits suitable for quantifying the amount of TNF ⁇ , IL-4, IL-5, IL-6 and/or IL-13 released are available from, for example, Biosource International, Inc., Camarillo, CA 93012 (see, e.g., Catalog Nos. KHC3011, KHC0042, KHC0052, KHC0061 and KHC0132).
- ELISA assay kits suitable for quantifying the amount of leukotriene C4 (LTC4) released from cells are available from Cayman Chemical Co., Ann Arbor, MI 48108 (see, e.g., Catalog No. 520211).
- active 2,4-pyrimidinediamine compounds of the invention will exhibit IC 50 S with respect to FceRI-mediated degranulation and/or mediator release or synthesis of about 20 ⁇ M or lower, as measured in an in vitro assay, such as one of the in vitro assays described above or in the Examples section.
- an in vitro assay such as one of the in vitro assays described above or in the Examples section.
- compounds which exhibit lower IC 50 S for example on the order of 10 ⁇ M, 1 ⁇ M, 100 nM, 10 nM, 1 nM, or even lower, are particularly useful.
- the various mediators discussed above may induce different adverse effects or exhibit different potencies with respect to the same adverse effect.
- the lipid mediator LTC4 is a potent vasoconstrictor - it is approximately 1000-fold more potent at inducing vasoconstriction than histamine.
- cytokines can also cause tissue remodeling and cell proliferation.
- One particularly useful class of compounds includes those 2,4-pyrimidinediamine compounds that inhibit the release of immediate granule-specific mediators and late stage mediators with approximately equivalent IC 50 S. By approximately equivalent is meant that the IC 50 S for each mediator type are within about a 10-fold range of one another.
- Another particularly useful class of compounds includes those 2,4-pyrimidinediamine compounds that inhibit the release of immediate granule-specific mediators, lipid mediators and cytokine mediators with approximately equivalent IC 50 S.
- such compounds inhibit the release of the following mediators with approximately equivalent IC 5 os: histamine, tryptase, hexosaminidase, IL-4, IL-5, IL-6, IL-13, TNF ⁇ and LTC4.
- Such compounds are particularly useful for, among other things, ameliorating or avoiding altogether both the early and late stage responses associated with atopic or immediate Type I hypersensitivity reactions.
- the ability to inhibit the release of all desired types of mediators will reside in a single compound.
- mixtures of compounds can also be identified that achieve the same result.
- a first compound which inhibits the release of granule specific mediators may be used in combination with a second compound which inhibits the release and/or synthesis of cytokine mediators.
- degranulation of mast and/or basophil cells can be induced by other agents.
- ionomycin a calcium ionophore that bypasses the early FceRI or Fc ⁇ RI signal transduction machinery of the cell, directly induces a calcium flux that triggers degranulation.
- activated PLC ⁇ initiates pathways that lead to, among other things, calcium ion mobilization and subsequent degranulation. As illustrated, this Ca + mobilization is triggered late in the FceRI signal transduction pathway.
- ionomycin directly induces Ca 2+ mobilization and a Ca 2+ flux that leads to degranulation.
- ionophores that induce degranulation in this manner include A23187.
- the ability of granulation-inducing ionophores such as ionomycin to bypass the early stages of the FceRI and/or Fc ⁇ RI signaling cascades may be used as a counter screen to identify active compounds of the invention that specifically exert their degranulation- inhibitory activity by blocking or inhibiting the early FceRI or Fc ⁇ RI signaling cascades, as discussed above.
- Compounds which specifically inhibit such early FceRI or Fc ⁇ RI- mediated degranulation inhibit not only degranulation and subsequent rapid release of histamine, tryptase and other granule contents, but also inhibit the pro-inflammatory
- Compounds of the invention capable of inhibiting the release of more than one type of mediator may be identified by determining the IC 50 with respect to a mediator representative of each class using the various in vitro assays described above (or other equivalent in vitro assays).
- Compounds of the invention which are capable of inhibiting the release of more than one mediator type will typically exhibit an IC 50 for each mediator type tested of less than about 20 ⁇ M.
- a compound which exhibits an IC 50 of 1 ⁇ M with respect to histamine release (IC 5 o hlstam e ) and an IC 50 of 1 nM with respect to leukotriene LTC4 synthesis and/or release (ICso LTC4 ) inhibits both immediate (granule-specific) and late stage mediator release.
- ICso LTC4 a compound that exhibits an ICso ⁇ of 10 ⁇ M, an IC 50 LTC4 of 1 ⁇ M and an ⁇ Cso ⁇ of 1 ⁇ M inhibits immediate (granule-specific), lipid and cytokine mediator release.
- the ability of the compounds to inhibit Fc ⁇ RI signal transduction may be confirmed in assays similar to those described above, with the exception that the Fc ⁇ RI signaling cascade is activated, for example by incubating the cells with IgG and an IgG-specific allergen or antibody, instead of IgE and an IgE-specific allergen or antibody.
- Suitable cell types, activating agents and agents to quantify to confirm inhibition of other Fc receptors, such as Fc receptors that comprise a gamma homodimer, • will be apparent to those of skill in the art.
- Compounds of the invention that specifically inhibit early FceRI and/or Fc ⁇ RI- mediated degranulation are those compounds that inhibit FceRI and/or Fc ⁇ RI-mediated degranulation (for example, have an IC 50 of less than about 20 ⁇ M with respect to the release of a granule-specific mediator or component as measured in an in vitro assay with cells stimulated with an IgE or IgG binding agent) but that do not appreciably inhibit ionophore-induced degranulation.
- compounds are considered to not appreciably inhibit ionophore-induced degranulation if they exhibit an IC 50 of ionophore- induced degranulation of greater than about 20 ⁇ M, as measured in an in vitro assay.
- active compounds that exhibit even higher ICsos of ionophore-induced degranulation, or that do not inhibit ionophore-induced degranulation at all, are particularly useful.
- compounds are considered to not appreciably inhibit ionophore-induced degranulation if they exhibit a greater than 10-fold difference in their IC 50 S of FceRI and/or Fc ⁇ RI-mediated degranulation and ionophore-induced degranulation, as measured in an in vitro assay.
- Assays suitable for determining the IC 50 of ionophore- induced degranulation include any of the previously-described degranulation assays, with the modification that the cells are stimulated or activated with a degranulation-inducing calcium ionophore such as ionomycin or A23187 (A.G. Scientific, San Diego, CA) instead of anti-IgE antibodies or an IgE-specific allergen.
- a degranulation-inducing calcium ionophore such as ionomycin or A23187 (A.G. Scientific, San Diego, CA) instead of anti-IgE antibodies or an IgE-specific allergen.
- Specific assays for assessing the ability of a particular 2,4-pyrimidinediamine compound of the invention to inhibit ionophore- induced degranulation are provided in the Examples section.
- compounds which exhibit a high degree of selectivity of FceRI-mediated degranulation find particular use, as such compounds selectively target the FceRI cascade and do not interfere with other degranulation mechanisms.
- compounds which exhibit a high degree of selectivity of Fc ⁇ RI- mediated degranulation find particular use, as such compounds selectively target the Fc ⁇ RI cascade and do not interfere with other degranulation mechanisms.
- Compounds which exhibit a high degree of selectivity are generally 10-fold or more selective for FceRI- or Fc ⁇ RI -mediated degranulation over ionophore-induced degranulation, such as ionomycin- induced degranulation.
- the activity of the 2,4-pyrimidinediamine compounds of the invention may also be confirmed in biochemical or cellular assays of Syk kinase activity.
- Syk kinase phosphorylates LAT and PLC-gamma 1, which leads to, among other things, degranulation. Any of these activities may be used to confirm the activity of the 2,4-pyrimidinediamine compounds of the invention.
- the activity is confirmed by contacting an isolated Syk kinase, or an active fragment thereof with a 2,4-pyrimidinediamine compound in the presence of a Syk kinase substrate (e.g., a synthetic peptide or a protein that is known to be phophorylated by Syk in a signaling cascade) and assessing whether the Syk kinase phosphorylated the substrate.
- a Syk kinase substrate e.g., a synthetic peptide or a protein that is known to be phophorylated by Syk in a signaling cascade
- the assay may be carried out with cells that express a Syk kinase.
- the cells may express the Syk kinase endogenously or they may be engineered to express a recombinant Syk kinase.
- the cells may optionally also express the Syk kinase substrate.
- compounds that are Syk kinase inhibitors will exhibit an IC5 0 with respect to a Syk kinase activity, such as the ability of Syk kinase to phosphorylate a synthetic or endogenous substrate, in an in vitro or cellular assay in the range of about 20 ⁇ M or less.
- a Syk kinase activity such as the ability of Syk kinase to phosphorylate a synthetic or endogenous substrate
- in vitro or cellular assay in the range of about 20 ⁇ M or less.
- Skilled artisans will appreciate that compounds that exhibit lower IC50s, such as in the range of 10 ⁇ M, l ⁇ M, 100 nM, 10 nM, 1 nM, or even lower, are particularly useful.
- the active compounds of the invention inhibit Fc receptor signaling cascades, especially those Fc receptors including a gamma homodimer, such as the FceRI and or Fc ⁇ RI signaling cascades, that lead to, among other things, the release and/or synthesis of chemical mediators from cells, either via degranulation or other processes.
- the active compounds are also potent inhibitors of Syk kinase.
- the active compounds of the invention may be used in a variety of in vitro, in vivo and ex vivo contexts to regulate or inhibit Syk kinase, signaling cascades in which Syk kinase plays a role, Fc receptor signaling cascades, and the biological responses effected by such signaling cascades.
- the compounds may be used to inhibit Syk kinase, either in vitro or in vivo, in virtually any cell type expressing Syk kinase. They may also be used to regulate signal transduction cascades in which Syk kinase plays a role.
- Such Syk-dependent signal transduction cascades include, but are not limited to, the FceRI, Fc ⁇ RI, Fc ⁇ RIII, BCR and integrin signal transduction cascades.
- the compounds may also be used in vitro or in vivo to regulate, and in particular inhibit, cellular or biological responses effected by such Syk-dependent signal transduction cascades.
- Such cellular or biological responses include, but are not limited to, respiratory burst, cellular adhesion, cellular degranulation, cell spreading, cell migration, cell aggregation, phagcytosis, cytokine synthesis and release, cell maturation and Ca 2+ flux.
- the compounds may be used to inhibit Syk kinase in vivo as a therapeutic approach towards the treatment or prevention of diseases mediated, either wholly or in part, by a Syk kinase activity.
- Syk kinase mediated diseases that may be treated or prevented with the compounds are those discussed in more detail, below.
- the active compounds may be used to regulate or inhibit the Fc receptor signaling cascades and/or FceRI- and/or Fc ⁇ RI-mediated degranulation as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by and/or associated with the release or synthesis of chemical mediators of such Fc receptor signaling cascades or degranulation.
- Such treatments may be administered to animals in veterinary contexts or to humans.
- Diseases that are characterized by, caused by or associated with such mediator release, synthesis or degranulation, and that can therefore be treated or prevented with the active compounds include, by way of example and not limitation, atopy or anaphylactic hypersensitivity or allergic reactions, allergies (e.g., allergic conjunctivitis, allergic rhinitis, atopic asthma, atopic dermatitis and food allergies), low grade scarring (e.g., of scleroderma, increased fibrosis, keloids, post-surgical scars, pulmonary fibrosis, vascular spasms, migraine, reperfusion injury and post myocardial infarction), diseases associated with tissue destruction (e.g. , of COPD, cardiobronchitis and post myocardial infarction), diseases associated with tissue inflammation (e.g., irritable bowel syndrome, spastic colon and inflammatory bowel disease), inflammation and scarring.
- atopy or anaphylactic hypersensitivity or allergic reactions include, by way of example and not limitation,
- autoimmune diseases that may be treated or prevented with the 2,4-pyrimidinediamine compounds generally include those disorders involving tissue injury that occurs as a result of a humoral and/or cell-mediated response to immunogens or antigens of endogenous and/or exogenous origin. Such diseases are frequently referred to as diseases involving the nonanaphylactic (i.e., Type II, Type III and or Type IV) hypersensitivity reactions.
- nonanaphylactic i.e., Type II, Type III and or Type IV
- Type I hypersensitivity reactions generally result from the release of pharmacologically active substances, such as histamine, from mast and/or basophil cells following contact with a specific exogenous antigen.
- pharmacologically active substances such as histamine
- Type II hypersensitivity reactions also referred to as cytotoxic, cytolytic complement-dependent or cell-stimulating hypersensitivity reactions
- Diseases that are commonly associated with Type II hypersensitivity reactions include, but are not limited, to autoimmune hemolytic anemia, erythroblastosis fetalis and Goodpasture's disease.
- Type III hypersensitivity reactions (also referred to as toxic complex, soluble complex, or immune complex hypersensitivity reactions) result from the deposition of soluble circulating antigen-immunoglobulin complexes in vessels or in tissues, with accompanying acute inflammatory reactions at the site of immune complex deposition.
- Non-limiting examples of prototypical Type III reaction diseases include the Arthus reaction, rheumatoid arthritis, serum sickness, systemic lupus erythematosis, certain types of glomerulonephritis, multiple sclerosis andbullous pemphingoid.
- Type IV hypersensitivity reactions (frequently called cellular, cell-mediated, delayed, or tuberculin-type hypersensitivity reactions) are caused by sensitized T- lymphocytes which result from contact with a specific antigen.
- diseases cited as involving Type IV reactions are contact dermatitis and allograft rejection.
- Autoimmune diseases associated with any of the above nonanaphylactic hypersensitivity reactions may be treated or prevented with the 2,4-pyrimidinediamine compounds of the invention.
- the methods may be used to treat or prevent those autoimmune diseases frequently characterized as single organ or single cell-type autoimmune disorders including, but not limited to: Hashimoto's thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia, myasthenia gravis, Graves' disease, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous glomerulopathy, as well as those autoimmune diseases frequently characterized as involving systemic autoimmune disorder, which include but are not limited to: systemic lupus erythematosis, rheumatoid arthritis, Sjogren's syndrome
- rheumatoid arthritis typically results in swelling, pain, loss of motion and tenderness of target joints throughout the body.
- RA is characterized by chronically inflamed synovium that is densely crowded with lymphocytes.
- the synovial membrane which is typically one cell layer thick, becomes intensely cellular and assumes a form similar to lymphoid tissue, including dentritic cells, T-, B- and NK cells, macrophages and clusters of plasma cells.
- the methods may be used to treat or ameliorate any one, several or all of these symptoms of RA.
- the methods are considered to provide therapeutic benefit (discussed more generally, infra) when a reduction or amelioration of any of the symptoms commonly associated with RA is achieved, regardless of whether the treatment results in a concomitant treatment of the underlying RA and/or a reduction in the amount of circulating rheumatoid factor ("RF").
- RF rheumatoid factor
- systemic lupus erythematosis is typically associated with symptoms such as fever, joint pain (arthralgias), arthritis, and serositis (pleurisy or pericarditis).
- SLE systemic lupus erythematosis
- the methods are considered to provide therapeutic benefit when a reduction or amelioration of any of the symptoms commonly associated with SLE are achieved, regardless of whether the treatment results in a concomitant treatment of the underlying SLE.
- MS multiple sclerosis
- multiple sclerosis cripples the patient by disturbing visual acuity; stimulating double vision; disturbing motor functions affecting walking and use of the hands; producing bowel and bladder incontinence; spasticity; and sensory deficits (touch, pain and temperature sensitivity).
- the methods are considered to provide therapeutic benefit when an improvement or a reduction in the progression of any one or more of the crippling effects commonly associated with MS is achieved, regardless of whether the treatment results in a concomitant treatment of the underlying MS.
- the active compounds When used to treat or prevent such diseases, the active compounds may be administered singly, as mixtures of one or more active compounds or in mixture or combination with other agents useful for treating such diseases and/or the symptoms associated with such diseases.
- the active compounds may also be administered in mixture or in combination with agents useful to treat other disorders or maladies, such as steroids, membrane stablizers, 5LO inhibitors, leukotriene synthesis and receptor inhibitors, inhibitors of IgE isotype switching or IgE synthesis, IgG isotype switching or IgG synthesis, ⁇ -agonists, tryptase inhibitors, aspirin, COX inhibitors, methotrexate, anti-TNF drugs, retuxin, PD4 inhibitors, p38 inhibitors, PDE4 inhibitors, and antihistamines, to name a few.
- the active compounds may be administered er se in the form of prodrugs or as pharmaceutical compositions, comprising an active compound or prodrug.
- compositions comprising the active compounds of the invention (or prodrugs thereof) may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making levigating, emulsifying, encapsulating, entrapping or lyophilization processes.
- the compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
- the active compound or prodrug may be formulated in the pharmaceutical compositions er se, or in the form of a hydrate, solvate, N-oxide or pharmaceutically acceptable salt, as previously described.
- such salts are more soluble in aqueous solutions than the corresponding free acids and bases, but salts having lower solubility than the corresponding free acids and bases may also be formed.
- compositions of the invention may take a form suitable for virtually any mode of administration, including, for example, topical, ocular, oral, buccal, systemic, nasal, injection, transdermal, rectal, vaginal, etc., or a form suitable for administration by inhalation or insufflation.
- topical administration the active compound(s) or prodrug(s) may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.
- Systemic formulations include those designed for administration by injection, e.g., subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal oral or pulmonary administration.
- Useful injectable preparations include sterile suspensions, solutions or emulsions of the active compound(s) in aqueous or oily vehicles.
- the compositions may also contain formulating agents, such as suspending, stabilizing and/or dispersing agent.
- the formulations for injection may be presented in unit dosage form, e.g., in ampules or in multidose containers, and may contain added preservatives.
- the injectable formulation may be provided in powder form for reconstitution with a suitable vehicle, including but not limited to sterile pyrogen free water, buffer, dextrose solution, etc., before use.
- a suitable vehicle including but not limited to sterile pyrogen free water, buffer, dextrose solution, etc.
- the active compound(s) may be dried by any art-known technique, such as lyophilization, and reconstituted prior to use.
- penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are known in the art.
- the pharmaceutical compositions may take the form of, for example, lozenges, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate).
- binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants e.g., magnesium stearate, talc or silica
- disintegrants e.g
- Liquid preparations for oral administration may take the form of, for example, elixirs, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, cremophoreTM or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid).
- the preparations may also contain buffer salts, preservatives, flavoring, coloring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound or prodrug, as is well known.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the active compound(s) may be formulated as solutions (for retention enemas) suppositories or ointments containing conventional suppository bases such as cocoa butter or other glycerides.
- the active compound(s) or prodrug(s) can be conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, fluorocarbons, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, fluorocarbons, carbon dioxide or other suitable gas.
- the dosage unit may be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- a specific example of an aqueous suspension formulation suitable for nasal administration using commercially-available nasal spray devices includes the following ingredients: active compound or prodrug (0.5-20 mg/ml); benzalkonium chloride (0.1-0.2 mg/mL); polysorbate 80 (TWEEN® 80; 0.5-5 mg/ml); carboxymethylcellulose sodium or microcrystalline cellulose (1-15 mg/ml); phenylethanol (1-4 mg/ml); and dextrose (20-50 mg/ml).
- the pH of the final suspension can be adjusted to range from about pH5 to pH7, with a pH of about pH 5.5 being typical.
- an aqueous suspension suitable for administration of the compounds via inhalation, and in particular for such administration of Compound R921218 contains 1-20 mg/mL Compound or prodrug, 0.1-1% (v/v) Polysorbate 80 (TWEEN®80), 50 mM citrate and/or 0.9% sodium chloride.
- the active compound(s) or prodrug(s) may be formulated as a solution, emulsion, suspension, etc. suitable for administration to the eye.
- a variety of vehicles suitable for administering compounds to the eye are known in the art. Specific non-limiting examples are described in U.S. Patent No. 6,261,547; U.S. Patent No. 6,197,934; U.S. Patent No. 6,056,950; U.S. Patent No. 5,800,807; U.S. Patent No. 5,776,445; U.S. Patent No. 5,698,219; U.S. Patent No. 5,521,222; U.S. Patent No. 5,403,841; U.S. Patent No. 5,077,033; U.S. Patent No. 4,882,150; and U.S. Patent No. 4,738,851.
- the active compound(s) or prodrug(s) can be formulated as a depot preparation for administration by implantation or intramuscular injection.
- the active ingredient may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, e.g., as a sparingly soluble salt.
- transdermal delivery systems manufactured as an adhesive disc or patch which slowly releases the active compound(s) for percutaneous absorption may be used.
- permeation enhancers may be used to facilitate transdermal penetration of the active compound(s). Suitable transdermal patches are described in for example, U.S. Patent No.
- Liposomes and emulsions are well-known examples of delivery vehicles that may be used to deliver active compound(s) or prodrug(s).
- Certain organic solvents such as dimethylsulfoxide (DMSO) may also be employed, although usually at the cost of greater toxicity.
- DMSO dimethylsulfoxide
- the pharmaceutical compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active compound(s).
- the pack may, for example, comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the active compound(s) or prodrug(s) of the invention, or compositions thereof, will generally be used in an amount effective to achieve the intended result, for example in an amount effective to treat or prevent the particular disease being treated.
- the compound(s) may be administered therapeutically to achieve therapeutic benefit or prophylactically to achieve prophylactic benefit.
- therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated and/or eradication or amelioration of one or more of the symptoms associated with the underlying disorder such that the patient reports an improvement in feeling or condition, notwithstanding that the patient may still be afflicted with the underlying disorder.
- admimstration of a compound to a patient suffering from an allergy provides therapeutic benefit not only when the underlying allergic response is eradicated or ameliorated, but also when the patient reports a decrease in the severity or duration of the symptoms associated with the allergy following exposure to the allergen.
- therapeutic benefit in the context of asthma includes an improvement in respiration following the onset of an asthmatic attack, or a reduction in the frequency or severity of asthmatic episodes.
- Therapeutic benefit also includes halting or slowing the progression of the disease, regardless of whether improvement is realized.
- the compound may be administered to a patient at risk of developing one of the previously described diseases. For example, if it is unknown whether a patient is allergic to a particular drug, the compound may be administered prior to administration of the drug to avoid or ameliorate an allergic response to the drug.
- prophylactic administration may be applied to avoid the onset of symptoms in a patient diagnosed with the underlying disorder. For example, a compound may be administered to an allergy sufferer prior to expected exposure to the allergen.
- Compounds may also be administered prophylactically to healthy individuals who are repeatedly exposed to agents known to one of the above-described maladies to prevent the onset of the disorder.
- a compound may be administered to a healthy individual who is repeatedly exposed to an allergen known to induce allergies, such as latex, in an effort to prevent the individual from developing an allergy.
- a compound may be administered to a patient suffering from asthma prior to partaking in activities which trigger asthma attacks to lessen the severity of, or avoid altogether, an asthmatic episode.
- the amount of compound administered will depend upon a variety of factors, including, for example, the particular indication being treated, the mode of administration, whether the desired benefit is prophylactic or therapeutic, the severity of the indication being treated and the age and weight of the patient, the bioavailability of the particular active compound, etc. Determination of an effective dosage is well within the capabilities of those skilled in the art.
- Effective dosages may be estimated initially from in vitro assays.
- an initial dosage for use in animals may be formulated to achieve a circulating blood or serum concentration of active compound that is at or above an IC 50 of the particular compound as measured in as in vitro assay, such as the in vitro CHMC or BMMC and other in vitro assays described in the Examples section.
- Calculating dosages to achieve such circulating blood or serum concentrations taking into account the bioavailability of the particular compound is well within the capabilities of skilled artisans.
- the reader is referred to Fingl & Woodbury, "General Principles," In: Goodman and Gilman 's The Pharmaceutical Basis of Therapeutics, Chapter 1, pp. 1-46, latest edition, Pagamonon Press, and the references cited therein.
- Initial dosages can also be estimated from in vivo data, such as animal models.
- Animal models useful for testing the efficacy of compounds to treat or prevent the various diseases described above are well-known in the art. Suitable animal models of hypersensitivity or allergic reactions are described in Foster, 1995, Allergy 50(21Suppl):6- 9, discussion 34-38 and Tumas et al, 2001, J. Allergy Clin. Immunol. 107(6):1025-1033. Suitable animal models of allergic rhinitis are described in Szelenyi et al, 2000, Arzneiffenforschung 50(11): 1037-42; Kawaguchi et al, 1994, Clin. Exp.
- Suitable animal models of atopic disorders such as atopic dermatitis, atopic eczema and atopic asthma are described in Chan et al, 2001, J. Invest. Dermatol. 117(4):977-983 and Suto et al, 1999, Int. Arch. Allergy Immunol. 120(Suppl l):70-75. Ordinarily skilled artisans can routinely adapt such information to determine dosages suitable for human administration. Additional suitable animal models are described in the Examples section.
- Dosage amounts will typically be in the range of from about 0.0001 or 0.001 or 0.01 mg/kg/day to about 100 mg/kg/day, but may be higher or lower, depending upon, among other factors, the activity of the compound, its bioavailability, the mode of administration and various factors discussed above. Dosage amount and interval may be adjusted individually to provide plasma levels of the compound(s) which are sufficient to maintain therapeutic or prophylactic effect.
- the compounds may be administered once per week, several times per week (e.g., every other day), once per day or multiple times per day, depending upon, among other things, the mode of administration, the specific indication being treated and the judgment of the prescribing physician.
- the effective local concentration of active compound(s) may not be related to plasma concentration. Skilled artisans will be able to optimize effective local dosages without undue experimentation.
- the compound(s) will provide therapeutic or prophylactic benefit without causing substantial toxicity.
- Toxicity of the compound(s) may be determined using standard pharmaceutical procedures.
- the dose ratio between toxic and therapeutic (or prophylactic) effect is the therapeutic index.
- Compounds(s) that exhibit high therapeutic indices are preferred.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
Priority Applications (22)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA05001096A MXPA05001096A (es) | 2002-07-29 | 2003-07-29 | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
AT03784871T ATE451104T1 (de) | 2002-07-29 | 2003-07-29 | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
UAA200500801A UA82196C2 (uk) | 2002-07-29 | 2003-07-29 | Використання сполук 2,4-піримідиндіаміну для одержання лікарського засобу для лікування або запобігання аутоімунним хворобам |
DE60330466T DE60330466D1 (de) | 2002-07-29 | 2003-07-29 | VERFAHREN ZUR BEHANDLUNG ODER PRuVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN |
YU20050069A RS51752B (en) | 2002-07-29 | 2003-07-29 | METHODS OF TREATMENT AND PREVENTION OF AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINDIAMINE COMPOUNDS |
NZ537752A NZ537752A (en) | 2002-07-29 | 2003-07-29 | Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases |
SI200331762T SI1534286T1 (sl) | 2002-07-29 | 2003-07-29 | Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami |
AU2003265336A AU2003265336B8 (en) | 2002-07-29 | 2003-07-29 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
CA2492325A CA2492325C (en) | 2002-07-29 | 2003-07-29 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
EP03784871A EP1534286B1 (en) | 2002-07-29 | 2003-07-29 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
KR1020057001685A KR101297924B1 (ko) | 2002-07-29 | 2003-07-29 | 2,4-피리미딘디아민 화합물을 이용한 자가면역질환의 치료및 예방 방법 |
JP2005506142A JP2006514989A (ja) | 2002-07-29 | 2003-07-29 | 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法 |
BRPI0313059A BR0313059B8 (pt) | 2002-07-29 | 2003-07-29 | composto, e, composição farmacêutica |
DK03784871.0T DK1534286T3 (da) | 2002-07-29 | 2003-07-29 | Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser |
IL166241A IL166241A (en) | 2002-07-29 | 2003-07-29 | 2,4-pyrimidinediamine compounds for use in the treatment of autoimmune diseases |
IL16624103A IL166241A0 (en) | 2002-07-29 | 2003-07-29 | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
HRP20050089AA HRP20050089B1 (hr) | 2002-07-29 | 2005-01-26 | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
IS7669A IS2923B (is) | 2002-07-29 | 2005-01-27 | Aðferðir til að meðhöndla eða fyrirbyggja með 2,4-pýrimidíndíamínefnasamböndum sjálfsónæmissjúkdóma |
SE0500203A SE0500203L (sv) | 2002-07-29 | 2005-01-27 | Förfaranden för behandling eller förhindrande av autoimmunsjukdomar med 2,4-pyrimidindiaminföreningar |
NO20051069A NO332550B1 (no) | 2002-07-29 | 2005-02-28 | 2,4-Pyrimidindiamin-forbindelser for anvendelse ved behandling av en autoimmun sykdom forskjellig fra ulcerativ kolitt, Crohn's sykdom, inflammatorisk tarm og idiopatisk inflammatorisk tarmsykdom |
HK05110991.3A HK1079978A1 (en) | 2002-07-29 | 2005-12-01 | Methods of treating or preventing autoimmune diseases with 2,4- pyrimidinediamine compounds |
IL214607A IL214607A (en) | 2002-07-29 | 2011-08-11 | 4,2-pyrimidine diamine compounds and their use in the preparation of autoimmune disease drugs |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39967302P | 2002-07-29 | 2002-07-29 | |
US60/399,673 | 2002-07-29 | ||
US44394903P | 2003-01-31 | 2003-01-31 | |
US60/443,949 | 2003-01-31 | ||
US45233903P | 2003-03-06 | 2003-03-06 | |
US60/452,339 | 2003-03-06 | ||
US10/631,029 US7517886B2 (en) | 2002-07-29 | 2003-07-29 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US10/631,029 | 2003-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004014382A1 true WO2004014382A1 (en) | 2004-02-19 |
Family
ID=31721742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/024087 WO2004014382A1 (en) | 2002-07-29 | 2003-07-29 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
Country Status (25)
Cited By (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012294A1 (en) * | 2003-07-30 | 2005-02-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
WO2006028833A1 (en) * | 2004-09-01 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | Synthesis of 2,4-pyrimidinediamine compounds |
JP2006515298A (ja) * | 2002-12-20 | 2006-05-25 | ファイザー・プロダクツ・インク | 異常な細胞増殖を治療するためのピリミジン誘導体 |
US7060827B2 (en) | 2002-02-01 | 2006-06-13 | Rigel Pharmaceuticals, Inc. | Intermediates useful for making 2,4-pyrimidinediamine compounds |
WO2006078846A1 (en) * | 2005-01-19 | 2006-07-27 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
WO2007009681A1 (en) * | 2005-07-15 | 2007-01-25 | Glaxo Group Limited | 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES |
WO2007028445A1 (en) * | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
WO2007085540A1 (en) * | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2007120980A2 (en) | 2006-02-17 | 2007-10-25 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
WO2007132010A1 (de) * | 2006-05-15 | 2007-11-22 | Boehringer Ingelheim International Gmbh | 2, 4 -diamino pyrimidine als inhibitoren von zellzykluskinasen |
EP1883302A2 (en) * | 2005-05-03 | 2008-02-06 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
EP1890703A2 (en) * | 2005-06-14 | 2008-02-27 | Taigen Biotechnology | Pyrimidine compounds |
WO2008049123A2 (en) | 2006-10-19 | 2008-04-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
WO2008064274A1 (en) | 2006-11-21 | 2008-05-29 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
JP2008521817A (ja) * | 2004-11-24 | 2008-06-26 | ライジェル ファーマシューティカルズ, インコーポレイテッド | スピロ2,4−ピリミジンジアミン化合物およびその使用 |
JP2008523033A (ja) * | 2004-12-08 | 2008-07-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 2,4(4,6)ピリミジン誘導体 |
WO2008118823A2 (en) * | 2007-03-26 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2009029682A1 (en) * | 2007-08-28 | 2009-03-05 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
WO2009080638A2 (en) | 2007-12-20 | 2009-07-02 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
WO2009112490A1 (en) * | 2008-03-11 | 2009-09-17 | Cellzome Limited | Sulfonamides as zap-70 inhibitors |
WO2009136995A2 (en) | 2008-04-16 | 2009-11-12 | Portola Pharmaceuticals, Inc. | Inhibitors of syk protein kinase |
EP2154967A1 (en) * | 2007-04-16 | 2010-02-24 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
US7713975B1 (en) | 2005-01-12 | 2010-05-11 | Alcon, Inc. | 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases |
US7737157B2 (en) | 2008-08-29 | 2010-06-15 | Hutchison Medipharma Enterprises Limited | Pyrimidine compounds |
WO2010078369A2 (en) | 2008-12-30 | 2010-07-08 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine kinase inhibitors |
WO2010090875A1 (en) | 2009-01-21 | 2010-08-12 | Rigel Pharmaceuticals, Inc. | Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
US7799778B1 (en) | 2005-01-12 | 2010-09-21 | Alcon, Inc. | 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases |
US7812029B1 (en) | 2002-07-29 | 2010-10-12 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US7820654B2 (en) | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
US7863286B2 (en) | 2004-11-15 | 2011-01-04 | Rigel Pharmaceuticals, Inc. | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
WO2011002999A1 (en) | 2009-07-02 | 2011-01-06 | Rigel Pharmaceuticals, Inc. | Synthesis of n4- (2, 2-dimethyl-4- [ (dihydrogen phosphonoxy ] -3-oxo-5-pyrido [1, 4] oxazin-6-yl)-5-fluoro-n2- (3, 4, 5,-trimethoxyphenyl) -2, 4- pyrimidinediamine disodium salt |
WO2011009075A2 (en) | 2009-07-17 | 2011-01-20 | Rigel Pharmaceuticals, Inc. | Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
WO2011017178A1 (en) | 2009-07-28 | 2011-02-10 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2010142766A3 (en) * | 2009-06-10 | 2011-04-14 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
US7928109B2 (en) | 2007-04-18 | 2011-04-19 | Pfizer Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
WO2011063241A1 (en) | 2009-11-20 | 2011-05-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
WO2011068898A1 (en) | 2009-12-01 | 2011-06-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
WO2011130390A1 (en) | 2010-04-13 | 2011-10-20 | Rigel Pharmaceuticals, Inc. | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
WO2012012619A1 (en) | 2010-07-21 | 2012-01-26 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
WO2012015972A1 (en) | 2010-07-28 | 2012-02-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
JP2012503604A (ja) * | 2008-09-23 | 2012-02-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 三環式カルバメートjak阻害剤 |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8138199B2 (en) | 2005-11-01 | 2012-03-20 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8148391B2 (en) | 2006-10-23 | 2012-04-03 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors |
AU2006264958B2 (en) * | 2005-07-01 | 2012-05-03 | Boehringer Ingelheim International Gmbh | 2,4-diamino-pyrimidines used as aurora inhibitors |
WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
WO2012061418A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
WO2012061428A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8309566B2 (en) | 2008-02-15 | 2012-11-13 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
US8324200B2 (en) | 2009-01-23 | 2012-12-04 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8372971B2 (en) | 2004-08-25 | 2013-02-12 | Targegen, Inc. | Heterocyclic compounds and methods of use |
EP2562163A1 (en) | 2008-01-22 | 2013-02-27 | Dow AgroSciences LLC | 5-fluoro pyrimidine derivatives as fungicides |
US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
WO2013078466A1 (en) | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
US8481536B2 (en) | 2004-04-08 | 2013-07-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
US8563568B2 (en) | 2010-08-10 | 2013-10-22 | Celgene Avilomics Research, Inc. | Besylate salt of a BTK inhibitor |
WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
US8604021B2 (en) | 2005-01-25 | 2013-12-10 | Oren Becker | Substituted arylamine compounds and methods of treatment |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2014089112A1 (en) | 2012-12-04 | 2014-06-12 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
WO2014116973A1 (en) | 2013-01-25 | 2014-07-31 | Rigel Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory bowel diseases |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
WO2014151900A1 (en) | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
US8975249B2 (en) | 2010-11-01 | 2015-03-10 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
US8993585B2 (en) | 2007-07-17 | 2015-03-31 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
US9012462B2 (en) | 2008-05-21 | 2015-04-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9056839B2 (en) | 2012-03-15 | 2015-06-16 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US9108927B2 (en) | 2012-03-15 | 2015-08-18 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9139534B2 (en) | 2011-04-22 | 2015-09-22 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US9365524B2 (en) | 2014-01-30 | 2016-06-14 | Signal Pharmaceuticals, Llc | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9513297B2 (en) | 2014-12-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-Jun N-terminal kinase in skin |
US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9593082B2 (en) | 2005-06-08 | 2017-03-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
US9708318B2 (en) | 2015-02-20 | 2017-07-18 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9796685B2 (en) | 2014-12-16 | 2017-10-24 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9834571B2 (en) | 2012-05-05 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9890156B2 (en) | 2015-02-20 | 2018-02-13 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
US10252981B2 (en) | 2015-07-24 | 2019-04-09 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
US10391094B2 (en) | 2010-11-07 | 2019-08-27 | Impact Biomedicines, Inc. | Compositions and methods for treating myelofibrosis |
CN110746402A (zh) * | 2019-09-21 | 2020-02-04 | 温州医科大学 | 一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用 |
US10611762B2 (en) | 2017-05-26 | 2020-04-07 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US10689351B2 (en) | 2015-01-29 | 2020-06-23 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
WO2020243612A1 (en) | 2019-05-29 | 2020-12-03 | Rigel Pharmaceuticals, Inc. | Method of preventing and treating thrombosis |
WO2021026451A1 (en) | 2019-08-08 | 2021-02-11 | Rigel Pharmaceuticals, Inc. | Compounds and method for treating cytokine release syndrome |
WO2021030526A1 (en) | 2019-08-14 | 2021-02-18 | Rigel Pharmaceuticals, Inc. | Method of blocking or ameliorating cytokine release syndrome |
US11001588B2 (en) | 2018-09-19 | 2021-05-11 | Forma Therapeutics, Inc. | Activating pyruvate kinase R and mutants thereof |
US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
US11071725B2 (en) | 2018-09-19 | 2021-07-27 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US20230030115A1 (en) * | 2017-06-30 | 2023-02-02 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US12024517B2 (en) | 2021-10-18 | 2024-07-02 | Incyte Corporation | Salts of an FGFR inhibitor |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006508997A (ja) * | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Chk−、Pdk−およびAkt−阻害性ピリミジン、それらの製造および薬剤としての使用 |
CL2004000303A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
BRPI0412347A (pt) * | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | 2-aminofenil-4-fenilpiridinas como inibidores de quinase |
ATE506953T1 (de) * | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
JP4607879B2 (ja) * | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン |
US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
ES2279500T3 (es) * | 2005-06-17 | 2007-08-16 | Magneti Marelli Powertrain S.P.A. | Inyector de carburante. |
US8246984B2 (en) * | 2005-12-06 | 2012-08-21 | Rigel Pharmaceuticals, Inc. | Formulation of insoluble small molecule therapeutics in lipid-based carriers |
US7947698B2 (en) | 2007-03-23 | 2011-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
ES2369596T3 (es) * | 2007-05-04 | 2011-12-02 | Astrazeneca Ab | Derivados de amino-tiazolil-pirimidina y su uso para el tratamiento del cáncer. |
CN101801965B (zh) * | 2007-08-17 | 2014-07-30 | 株式会社Lg生命科学 | 作为细胞坏死抑制剂的吲哚化合物 |
CN101659659B (zh) * | 2008-08-29 | 2013-01-02 | 和记黄埔医药(上海)有限公司 | 嘧啶衍生物及其医药用途 |
MX353747B (es) | 2009-08-17 | 2018-01-26 | Memorial Sloan Kettering Cancer Center Star | Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos. |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
PT2683385T (pt) | 2011-03-10 | 2018-10-19 | Rigel Pharmaceuticals Inc | Pirimidinadiaminas 2,4-substituídas para utilização no lúpus discoide |
AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
WO2012135641A2 (en) | 2011-03-30 | 2012-10-04 | H. Lee Moffitt Cancer Center And Research Institute | Aurora kinase inhibitors and methods of making and using thereof |
EA028432B1 (ru) | 2011-07-28 | 2017-11-30 | Райджел Фармасьютикалз, Инк. | Новые составы на основе (триметоксифениламино)пиримидинилов |
CA2846187A1 (en) | 2011-08-23 | 2013-02-28 | Endo Pharmaceuticals Inc. | Pyrimido-pyridazinone compounds and use thereof |
MY187101A (en) | 2012-06-15 | 2021-08-31 | Commw Scient Ind Res Org | Production of long chain polyunsaturated fatty acids in plant cells |
KR101446742B1 (ko) | 2012-08-10 | 2014-10-01 | 한국화학연구원 | N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
WO2014043257A1 (en) | 2012-09-12 | 2014-03-20 | Rigel Pharmaceuticals, Inc. | Treatment for vitiligo |
US9748604B2 (en) | 2012-10-19 | 2017-08-29 | The University Of North Carolina At Chapel Hill | Ion conducting polymers and polymer blends for alkali metal ion batteries |
EP2915804B1 (en) * | 2012-10-31 | 2019-03-27 | FUJIFILM Toyama Chemical Co., Ltd. | Novel amine derivative or salt thereof as tnf alpha inhibitors |
EP2970138B1 (en) | 2013-03-13 | 2019-01-16 | Canadian Blood Services | Pyrazole derivatives and their uses thereof |
EP2982001A2 (en) | 2013-04-01 | 2016-02-10 | The University of North Carolina At Chapel Hill | Ion conducting fluoropolymer carbonates for alkali metal ion batteries |
TWI667233B (zh) * | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
WO2015175707A1 (en) | 2014-05-13 | 2015-11-19 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
US9540312B2 (en) | 2015-02-03 | 2017-01-10 | Blue Current, Inc. | Non-flammable electrolyte composition including carbonate-terminated perfluoropolymer and phosphate-terminated or phosphonate-terminated perfluoropolymer and battery using same |
MX2017016619A (es) * | 2015-07-09 | 2018-05-15 | Merck Patent Gmbh | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. |
WO2017070796A1 (en) * | 2015-10-30 | 2017-05-04 | Trillium Therapeutics Inc. | Heterocycle derivatives and their use for the treatment of cns disorders |
CN109153650A (zh) * | 2016-04-15 | 2019-01-04 | Epizyme股份有限公司 | 作为ehmt1和ehmt2抑制剂的胺取代的芳基或杂芳基化合物 |
AU2018254577B2 (en) | 2017-04-21 | 2024-06-13 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
CN107417611A (zh) * | 2017-07-25 | 2017-12-01 | 广州大学 | 一种3‑(4‑甲氧基苯基)‑6‑甲氧基‑4‑氯‑5,7‑二溴喹啉的合成方法 |
CN111362928A (zh) * | 2018-12-26 | 2020-07-03 | 上海喆邺生物科技有限公司 | 2,4-二氨基嘧啶衍生物 |
US20220388968A1 (en) * | 2019-06-18 | 2022-12-08 | Purdue Research Foundation | Inhibitors of erythrocyte band 3 tyrosine phosphorylation and uses thereof |
CN112920124B (zh) * | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958935A (en) * | 1995-11-20 | 1999-09-28 | Celltech Therapeutics Limited | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors |
WO2000039101A1 (en) * | 1998-12-24 | 2000-07-06 | Astrazeneca Ab | Pyrimidine compounds |
WO2000058305A1 (en) * | 1999-03-26 | 2000-10-05 | Astrazeneca Ab | Novel compounds |
WO2001047897A1 (en) * | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Cytokine, especially tnf-alpha, inhibitors |
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
WO2001064656A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
GB2373186A (en) * | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
WO2003002544A1 (en) * | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
WO2003063794A2 (en) * | 2002-02-01 | 2003-08-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
WO2003076437A1 (de) * | 2002-03-11 | 2003-09-18 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
WO2003078404A1 (en) * | 2002-03-15 | 2003-09-25 | Novartis Ag | Pyrimidine derivatives |
Family Cites Families (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3159547A (en) | 1963-06-28 | 1964-12-01 | Abbott Lab | Method of lowering blood pressure with 4-(2-amino-4-pyrimidylamino)-benzene-sulfonamide |
US3320256A (en) | 1965-04-09 | 1967-05-16 | Hoffmann La Roche | Fluorinated imidazoo[1, 2-c]pyrimidines and pyrimido[1, 2-c]pyrimidines |
GR80171B (en) | 1983-08-29 | 1985-01-02 | Ciba Geigy Ag | N-(2-nitrophenyl)-4-aminopyrimidine derivatives process for the preparation thereof and use |
DE3618353A1 (de) | 1986-05-31 | 1987-12-03 | Hoechst Ag | Schaedlingsbekaempfungsmittel auf der basis von aminopyrimidin-derivaten sowie neue aminopyrimidin-verbindungen |
DE3868287D1 (de) | 1987-04-02 | 1992-03-19 | Ciba Geigy Ag | Reaktivfarbstoffe, deren herstellung und verwendung. |
SU1499883A1 (ru) | 1987-11-24 | 1991-10-23 | Научно-исследовательский институт фармакологии АМН СССР | Дихлоргидрат 2,4-бис-(п-трет-бутиланилино)-5-окси-6-метилпиримидина, обладающий анальгетической и противовоспалительной активностью |
HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
IE63502B1 (en) | 1989-04-21 | 1995-05-03 | Zeneca Ltd | Aminopyrimidine derivatives useful for treating cardiovascular disorders |
US4983608A (en) | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
US5179204A (en) | 1989-09-05 | 1993-01-12 | Hoechst-Roussel Pharmaceuticals Incorporated | N-substituted-4-pyrimidinamines and pyrimidinediamines |
JPH03127790A (ja) | 1989-10-11 | 1991-05-30 | Morishita Pharmaceut Co Ltd | N―(1h―テトラゾール―5―イル)―2―アニリノ―5―ピリミジンカルボキシアミド類及びその合成中間体 |
TW224941B (US07825116-20101102-C00023.png) | 1989-11-08 | 1994-06-11 | Yamanouchi Pharma Co Ltd | |
GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
CA2074864A1 (en) | 1991-07-30 | 1993-01-31 | Carmen Almansa | Tetralones with pharmacological activity |
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW287160B (US07825116-20101102-C00023.png) | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
BR9407799A (pt) | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
IL112290A (en) | 1994-01-12 | 1999-01-26 | Novartis Ag | Transformed aryl and the troiryl pyrimidines and herbicides containing them |
CA2150609C (en) | 1994-06-01 | 1998-12-08 | Mikiro Yanaka | Pyrimidine derivatives and pharmaceutical composition |
US5733932A (en) | 1995-01-06 | 1998-03-31 | The Picower Institute For Medical Research | Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions |
GB9516121D0 (en) | 1995-08-05 | 1995-10-04 | Pfizer Ltd | Organometallic addition to ketones |
TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
US6004985A (en) | 1996-10-09 | 1999-12-21 | Berlex Laboratories, Inc. | Thio acid derived monocylic N-heterocyclics as anticoagulants |
DE19710435A1 (de) * | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
GB9723859D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Compound,composition and use |
DE19750701A1 (de) | 1997-11-15 | 1999-05-20 | Dystar Textilfarben Gmbh & Co | Verfahren zur Umsetzung von fluorsubstituierten Heterocyclen mit Aminen in Gegenwart von Phasentransfer-Katalysatoren |
AU1507199A (en) | 1997-12-15 | 1999-07-05 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
US5985856A (en) | 1997-12-31 | 1999-11-16 | University Of Kansas | Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof |
NZ506417A (en) | 1998-02-17 | 2003-05-30 | Tularik Inc | Anti-viral pyrimidine derivatives |
WO1999046248A1 (en) * | 1998-03-09 | 1999-09-16 | Vertex Pharmaceuticals Incorporated | 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
JP2002506873A (ja) | 1998-03-18 | 2002-03-05 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 複素環式シグナル伝達阻害剤、それを含む組成物 |
SI0945443T1 (en) | 1998-03-27 | 2003-08-31 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
BRPI9909191B8 (pt) | 1998-03-27 | 2021-07-06 | Janssen Pharmaceutica Nv | derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende |
GB9806739D0 (en) | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
AU3213799A (en) | 1998-04-01 | 1999-10-18 | Du Pont Pharmaceuticals Company | Integrin antagonists |
CN1548436A (zh) | 1998-05-22 | 2004-11-24 | ʷ��˿�������ȳ�ķ����˾ | 新的2-烷基取代咪唑化合物 |
US6093743A (en) * | 1998-06-23 | 2000-07-25 | Medinox Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
CA2337999A1 (en) | 1998-06-30 | 2000-01-06 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
HUP0103386A3 (en) | 1998-08-21 | 2002-07-29 | Parker Hughes Inst St Paul | Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect |
ES2274634T3 (es) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
DE19851421A1 (de) | 1998-11-07 | 2000-05-11 | Boehringer Ingelheim Pharma | Neue Pyrimidine, deren Herstellung und Verwendung |
NZ511116A (en) | 1998-11-10 | 2003-08-29 | Janssen Pharmaceutica Nv | HIV replication inhibiting pyrimidines |
US6127376A (en) | 1998-12-04 | 2000-10-03 | Berlex Laboratories, Inc. | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
CA2369945A1 (en) | 1999-04-06 | 2000-10-12 | James L. Kelley | Neurotrophic thio substituted pyrimidines |
DE19917785A1 (de) | 1999-04-20 | 2000-10-26 | Bayer Ag | 2,4-Diamino-pyrimidin-Derivate |
AU5108000A (en) | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9918035D0 (en) | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
DE19945982A1 (de) | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
IL148801A0 (en) | 1999-09-24 | 2002-09-12 | Janssen Pharmaceutica Nv | Antiviral compositions |
PL354784A1 (en) | 1999-09-30 | 2004-02-23 | Neurogen Corporation | Certain alkylene diamine-substituted heterocycles |
WO2001030782A2 (en) | 1999-10-29 | 2001-05-03 | Syngenta Participations Ag | Novel herbicides |
WO2001045641A2 (en) | 1999-11-30 | 2001-06-28 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
CN1195755C (zh) | 1999-12-10 | 2005-04-06 | 辉瑞产品公司 | 吡咯并[2,3-d]嘧啶化合物 |
US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
US6362172B2 (en) | 2000-01-20 | 2002-03-26 | Bristol-Myers Squibb Company | Water soluble prodrugs of azole compounds |
GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6525051B2 (en) | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
US7034019B2 (en) | 2000-05-08 | 2006-04-25 | Janssen Pharmaceutica N.V. | Prodrugs of HIV replication inhibiting pyrimidines |
AU783981C (en) | 2000-05-08 | 2007-05-03 | Janssen Pharmaceutica N.V. | HIV replication inhibitors |
MXPA03000068A (es) | 2000-06-26 | 2003-09-25 | Pfizer Prod Inc | Compuestos de pirrolo (2,3-d)pirimidina como agentes inmunosupresores. |
GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
KR100876069B1 (ko) | 2000-09-15 | 2008-12-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물 |
US20020058029A1 (en) * | 2000-09-18 | 2002-05-16 | Nabil Hanna | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination |
WO2002043735A1 (en) | 2000-11-29 | 2002-06-06 | Parker Hughes Institute | Inhibitors of thrombin induced platelet aggregation |
US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
HU230574B1 (hu) | 2000-12-21 | 2023-11-28 | Novartis Ag | Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok |
MXPA03005610A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
WO2002064096A2 (en) | 2001-02-16 | 2002-08-22 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
WO2002066480A2 (en) | 2001-02-20 | 2002-08-29 | Astrazeneca Ab | 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
WO2002070662A2 (en) | 2001-03-02 | 2002-09-12 | Gpc Biotech Ag | Three hybrid assay system |
JP4291135B2 (ja) | 2001-05-29 | 2009-07-08 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Cdk阻害性ピリミジン、それらの製造および薬剤としての使用 |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
MXPA03010961A (es) | 2001-05-31 | 2004-02-27 | Vertex Pharma | Compuestos de tiazol utiles como inhibidores de proteinas cinasas. |
DE60214703T2 (de) | 2001-06-01 | 2007-09-13 | Vertex Pharmaceuticals Inc., Cambridge | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen |
DE60232510D1 (de) | 2001-06-15 | 2009-07-16 | Vertex Pharma | 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer |
WO2002102313A2 (en) | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
WO2003000186A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel phenylamino-pyrimidines and uses thereof |
KR100875380B1 (ko) | 2001-06-23 | 2008-12-23 | 아벤티스 파마슈티칼스 인크. | 단백질 키나제 억제제로서의 피롤로피리미딘 |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
WO2003032997A1 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
ES2330090T3 (es) | 2001-11-28 | 2009-12-04 | Btg International Limited | Agentes profilacticos o remedios para la enfermedad de alzheimer o unhibidores de la fibrosis de las proteinas amiloides que contiene compuestos de heteroarilo que contiene nitrogeno. |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
SE0104140D0 (sv) | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
US6924290B2 (en) | 2002-01-23 | 2005-08-02 | Bayer Pharmaceuticals Corporation | Rho-kinase inhibitors |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
WO2003066601A1 (en) | 2002-02-08 | 2003-08-14 | Smithkline Beecham Corporation | Pyrimidine compounds |
CA2477505A1 (en) | 2002-03-01 | 2003-09-12 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
GEP20074230B (en) | 2002-03-20 | 2007-11-12 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
WO2003095448A1 (en) | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
AU2003301758A1 (en) | 2002-05-06 | 2004-05-25 | Bayer Pharmaceuticals Corporation | Use of pyrimidine derivates for the manifacture of a medicament for the treatment of hyper-proliferative disorders |
MXPA04011048A (es) | 2002-05-06 | 2005-02-17 | Vertex Pharmaceutivals Inc | Tiadiazol o oxasiazoles y su uso como inhibidores de proteina cinasa jak. |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
AU2003231880A1 (en) | 2002-05-30 | 2003-12-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
CA2489648A1 (en) | 2002-06-17 | 2003-12-24 | Smithkline Beecham Corporation | Chemical process |
WO2004002964A1 (ja) | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
SG176311A1 (en) | 2002-07-29 | 2011-12-29 | Rigel Pharmaceuticals | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
WO2004014384A2 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
WO2004016597A2 (en) | 2002-08-14 | 2004-02-26 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
ATE454378T1 (de) | 2002-11-01 | 2010-01-15 | Vertex Pharma | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen |
CA2506773A1 (en) | 2002-11-04 | 2004-05-21 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyramidine derivatives as jak inhibitors |
AU2003286895A1 (en) | 2002-11-05 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
GB0226582D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
CA2506016C (en) | 2002-11-21 | 2009-03-17 | Pfizer Products Inc. | 3-amino-piperidine derivatives and processes for their preparation |
PL378246A1 (pl) | 2002-11-26 | 2006-03-20 | Pfizer Products Inc. | Sposób leczenia odrzucania przeszczepu |
JP2006508997A (ja) | 2002-11-28 | 2006-03-16 | シエーリング アクチエンゲゼルシャフト | Chk−、Pdk−およびAkt−阻害性ピリミジン、それらの製造および薬剤としての使用 |
WO2004050068A1 (en) | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
AU2003289330A1 (en) | 2002-12-13 | 2004-07-09 | Kyowa Hakko Kogyo Co., Ltd. | Preventives and/or remedies for central diseases |
WO2004058749A1 (en) | 2002-12-18 | 2004-07-15 | Vertex Pharmaceuticals Incorporated | Benzisoxazole derivatives useful as inhibitors of protein kinases |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
CA2513527C (en) | 2003-02-07 | 2012-08-14 | Janssen Pharmaceutica N.V. | Pyrimidine derivatives for the prevention of hiv infection |
CL2004000303A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih. |
US7514446B2 (en) | 2003-02-20 | 2009-04-07 | Smithkline Beecham Corporation | Pyrimidine compounds |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
US20050009817A1 (en) | 2003-04-30 | 2005-01-13 | Jennifer Savoy | Substituted heteroaryls |
GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
WO2005007621A2 (en) | 2003-05-30 | 2005-01-27 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
NZ545058A (en) | 2003-07-16 | 2008-05-30 | Janssen Pharmaceutica Nv | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
JP2007526894A (ja) | 2003-07-16 | 2007-09-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲンシンターゼキナーゼ3インヒビターとしてのトリアゾロピリミジン誘導体 |
US20070161637A1 (en) | 2003-07-22 | 2007-07-12 | Neurogen Corporation | Substituted pyridin-2-ylamine analogues |
US7442698B2 (en) * | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
BRPI0412347A (pt) | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | 2-aminofenil-4-fenilpiridinas como inibidores de quinase |
CN102358738A (zh) * | 2003-07-30 | 2012-02-22 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途 |
ATE506953T1 (de) | 2003-08-07 | 2011-05-15 | Rigel Pharmaceuticals Inc | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel |
JP4607879B2 (ja) | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な2,4−ピリミジンジアミン |
US7223759B2 (en) | 2003-09-15 | 2007-05-29 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
AU2004272288B2 (en) | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
WO2005027848A2 (en) | 2003-09-19 | 2005-03-31 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators |
EA009734B1 (ru) | 2003-09-25 | 2008-02-28 | Янссен Фармацевтика Н.В. | Производные пурина, ингибирующие репликацию вич |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
TW200529849A (en) | 2003-11-28 | 2005-09-16 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
JP2007514775A (ja) | 2003-12-19 | 2007-06-07 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 1−(2,4−ピリミジンジアミノ)−2−シクロペンタンカルボキサイミド合成中間体の立体異性体および立体異性体混合物 |
ZA200602666B (en) | 2004-01-12 | 2007-09-26 | Cytopia Res Pty Ltd | Selective kinase inhibitors |
GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
BRPI0507668A (pt) | 2004-02-14 | 2007-07-17 | Irm Llc | compostos e composições como inibidores de proteìna cinase |
US7607424B2 (en) * | 2004-02-17 | 2009-10-27 | Planet Eclipse Limited | Electro-magnetically operated rotating projectile loader |
US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
JP4812763B2 (ja) * | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
US20060047135A1 (en) | 2004-08-30 | 2006-03-02 | Chadwick Scott T | Process for preparing chloromethyl di-tert-butylphosphate |
EP1786783A1 (en) * | 2004-09-01 | 2007-05-23 | Rigel Pharmaceuticals, Inc. | Synthesis of 2,4-pyrimidinediamine compounds |
JP2008514571A (ja) | 2004-09-29 | 2008-05-08 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 細胞周期−キナーゼまたはレセプター−チロシン−キナーゼインヒビターとしての置換2−置換アニリノピリミジン類、それらの製造および薬剤としての使用 |
EP1817303A2 (en) | 2004-10-29 | 2007-08-15 | Rigel Pharmaceuticals, Inc. | Substituted pyridines with activity on syk kinase |
WO2006068770A1 (en) * | 2004-11-24 | 2006-06-29 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
AU2005322855B2 (en) | 2004-12-30 | 2012-09-20 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
CA2591948C (en) | 2005-01-19 | 2013-11-12 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US20060270694A1 (en) | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
US20070203161A1 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
ES2651349T3 (es) * | 2005-06-08 | 2018-01-25 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta JAK |
WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
MX2008000574A (es) | 2005-07-11 | 2008-03-14 | Sanofi Aventis | Nuevos derivados de 2,4-dianilinopirimidinas, la preparacion de los mismos, su uso como medicamentos, composiciones farmaceuticas y, en particular, como inhibidores ikk. |
PL1913009T3 (pl) | 2005-07-28 | 2010-10-29 | Intervet Int Bv | Nowe (tio)karbaminiany benzimidazolu o działaniu przeciwpasożytniczym i sposób ich wytwarzania |
JP4981673B2 (ja) | 2005-09-13 | 2012-07-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物およびその製造方法 |
CA2627242A1 (en) * | 2005-10-31 | 2007-05-10 | Rigel Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory disorders |
PT1951684T (pt) | 2005-11-01 | 2016-10-13 | Targegen Inc | Inibidores de cinases de tipo biaril-meta-pirimidina |
US7713987B2 (en) * | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
WO2007085540A1 (en) | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
WO2007120980A2 (en) * | 2006-02-17 | 2007-10-25 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
US7776855B2 (en) | 2006-07-27 | 2010-08-17 | Janssen Pharmaceutica N.V. | Antimicrobial oxazolidinone prodrugs |
-
2003
- 2003-07-29 SG SG2007044290A patent/SG176311A1/en unknown
- 2003-07-29 IL IL16624103A patent/IL166241A0/xx unknown
- 2003-07-29 ES ES03784871T patent/ES2337782T3/es not_active Expired - Lifetime
- 2003-07-29 ES ES10010732.5T patent/ES2445208T3/es not_active Expired - Lifetime
- 2003-07-29 RS YU20050069A patent/RS51752B/en unknown
- 2003-07-29 DE DE60330466T patent/DE60330466D1/de not_active Expired - Lifetime
- 2003-07-29 BR BRPI0313059A patent/BR0313059B8/pt active IP Right Grant
- 2003-07-29 WO PCT/US2003/024087 patent/WO2004014382A1/en active Application Filing
- 2003-07-29 US US10/631,029 patent/US7517886B2/en active Active
- 2003-07-29 NZ NZ537752A patent/NZ537752A/en not_active IP Right Cessation
- 2003-07-29 CN CN201310060555.0A patent/CN103169708B/zh not_active Expired - Lifetime
- 2003-07-29 IL IL166241A patent/IL166241A/en active IP Right Grant
- 2003-07-29 CN CNA038211203A patent/CN1678321A/zh active Pending
- 2003-07-29 DK DK03784871.0T patent/DK1534286T3/da active
- 2003-07-29 JP JP2005506142A patent/JP2006514989A/ja active Pending
- 2003-07-29 AT AT03784871T patent/ATE451104T1/de active
- 2003-07-29 EP EP03784871A patent/EP1534286B1/en not_active Expired - Lifetime
- 2003-07-29 AU AU2003265336A patent/AU2003265336B8/en not_active Expired
- 2003-07-29 CA CA2492325A patent/CA2492325C/en not_active Expired - Lifetime
- 2003-07-29 PL PL373455A patent/PL216744B1/pl unknown
- 2003-07-29 MX MXPA05001096A patent/MXPA05001096A/es active IP Right Grant
-
2005
- 2005-01-26 HR HRP20050089AA patent/HRP20050089B1/hr not_active IP Right Cessation
- 2005-01-27 SE SE0500203A patent/SE0500203L/sv not_active Application Discontinuation
- 2005-01-27 IS IS7669A patent/IS2923B/is unknown
- 2005-02-28 NO NO20051069A patent/NO332550B1/no not_active IP Right Cessation
- 2005-12-01 HK HK05110991.3A patent/HK1079978A1/xx not_active IP Right Cessation
-
2006
- 2006-10-05 US US11/539,101 patent/US7825116B2/en active Active
-
2008
- 2008-02-08 US US12/028,581 patent/US7812029B1/en not_active Expired - Lifetime
-
2010
- 2010-01-21 US US12/691,657 patent/US8158621B2/en not_active Expired - Fee Related
- 2010-03-09 CY CY20101100217T patent/CY1110292T1/el unknown
- 2010-07-05 JP JP2010152958A patent/JP5441841B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-11 IL IL214607A patent/IL214607A/en active IP Right Grant
- 2011-10-18 HK HK11111090.3A patent/HK1159472A1/xx not_active IP Right Cessation
-
2012
- 2012-03-13 US US13/418,696 patent/US8557806B2/en not_active Expired - Lifetime
-
2013
- 2013-05-24 RU RU2013123881A patent/RU2659777C9/ru active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5958935A (en) * | 1995-11-20 | 1999-09-28 | Celltech Therapeutics Limited | Substituted 2-anilinopyrimidines useful as protein kinase inhibitors |
WO2000039101A1 (en) * | 1998-12-24 | 2000-07-06 | Astrazeneca Ab | Pyrimidine compounds |
WO2000058305A1 (en) * | 1999-03-26 | 2000-10-05 | Astrazeneca Ab | Novel compounds |
WO2001047897A1 (en) * | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Cytokine, especially tnf-alpha, inhibitors |
WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
WO2001064656A1 (en) * | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
GB2373186A (en) * | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
WO2003002544A1 (en) * | 2001-06-26 | 2003-01-09 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
WO2003063794A2 (en) * | 2002-02-01 | 2003-08-07 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
WO2003076437A1 (de) * | 2002-03-11 | 2003-09-18 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
WO2003078404A1 (en) * | 2002-03-15 | 2003-09-25 | Novartis Ag | Pyrimidine derivatives |
Cited By (330)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8334296B2 (en) | 2002-02-01 | 2012-12-18 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7906644B2 (en) | 2002-02-01 | 2011-03-15 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US10709703B2 (en) | 2002-02-01 | 2020-07-14 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9416112B2 (en) | 2002-02-01 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9913842B2 (en) | 2002-02-01 | 2018-03-13 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7060827B2 (en) | 2002-02-01 | 2006-06-13 | Rigel Pharmaceuticals, Inc. | Intermediates useful for making 2,4-pyrimidinediamine compounds |
US7655797B2 (en) | 2002-02-01 | 2010-02-02 | Rigel Pharmaceuticals, Inc. | Intermediates for making 2,4-pyrimidinediamine compounds |
US10682350B2 (en) | 2002-02-01 | 2020-06-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US8835430B2 (en) | 2002-02-01 | 2014-09-16 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9018204B1 (en) | 2002-02-01 | 2015-04-28 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7803939B2 (en) | 2002-02-01 | 2010-09-28 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US9346765B2 (en) | 2002-02-01 | 2016-05-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7820819B2 (en) | 2002-02-01 | 2010-10-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and their uses |
US7825116B2 (en) | 2002-07-29 | 2010-11-02 | Rigel Pharmaceuticals, Inc. | N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines |
US7812029B1 (en) | 2002-07-29 | 2010-10-12 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US8557806B2 (en) | 2002-07-29 | 2013-10-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
JP2006515298A (ja) * | 2002-12-20 | 2006-05-25 | ファイザー・プロダクツ・インク | 異常な細胞増殖を治療するためのピリミジン誘導体 |
WO2005016893A3 (en) * | 2003-07-30 | 2005-06-09 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
US9751893B2 (en) | 2003-07-30 | 2017-09-05 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
WO2005012294A1 (en) * | 2003-07-30 | 2005-02-10 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
AU2011200367B2 (en) * | 2003-07-30 | 2012-07-26 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
US8481536B2 (en) | 2004-04-08 | 2013-07-09 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
US8546398B2 (en) | 2004-05-18 | 2013-10-01 | Rigel Pharmaceuticals, Inc. | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
US7754714B2 (en) | 2004-05-18 | 2010-07-13 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
US8372971B2 (en) | 2004-08-25 | 2013-02-12 | Targegen, Inc. | Heterocyclic compounds and methods of use |
WO2006028833A1 (en) * | 2004-09-01 | 2006-03-16 | Rigel Pharmaceuticals, Inc. | Synthesis of 2,4-pyrimidinediamine compounds |
US7820654B2 (en) | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
US7863286B2 (en) | 2004-11-15 | 2011-01-04 | Rigel Pharmaceuticals, Inc. | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
US8030483B2 (en) | 2004-11-15 | 2011-10-04 | Rigel Pharmaceuticals, Inc. | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
US8044054B2 (en) | 2004-11-15 | 2011-10-25 | Rigel Pharmaceuticals, Inc. | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
US8101627B2 (en) | 2004-11-15 | 2012-01-24 | Rigel Pharmaceuticals, Inc. | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
US7851480B2 (en) | 2004-11-24 | 2010-12-14 | Rigel Pharmaceuticals, Inc. | Spiro 2,4-pyrimidinediamine compounds and their uses |
JP2008521817A (ja) * | 2004-11-24 | 2008-06-26 | ライジェル ファーマシューティカルズ, インコーポレイテッド | スピロ2,4−ピリミジンジアミン化合物およびその使用 |
JP2008523033A (ja) * | 2004-12-08 | 2008-07-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 2,4(4,6)ピリミジン誘導体 |
US7713975B1 (en) | 2005-01-12 | 2010-05-11 | Alcon, Inc. | 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases |
US7906512B2 (en) | 2005-01-12 | 2011-03-15 | Alcon, Inc. | 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases |
US7799778B1 (en) | 2005-01-12 | 2010-09-21 | Alcon, Inc. | 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases |
KR101278397B1 (ko) * | 2005-01-19 | 2013-06-25 | 리겔 파마슈티칼스, 인크. | 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도 |
JP2008527048A (ja) * | 2005-01-19 | 2008-07-24 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用 |
WO2006078846A1 (en) * | 2005-01-19 | 2006-07-27 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US7989448B2 (en) | 2005-01-19 | 2011-08-02 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
AU2006206458B2 (en) * | 2005-01-19 | 2012-10-25 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US10577381B2 (en) | 2005-01-19 | 2020-03-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8211888B2 (en) | 2005-01-19 | 2012-07-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US9532998B2 (en) | 2005-01-19 | 2017-01-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8211889B2 (en) | 2005-01-19 | 2012-07-03 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
EP2161275A1 (en) * | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
JP4801096B2 (ja) * | 2005-01-19 | 2011-10-26 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用 |
US8476263B2 (en) | 2005-01-19 | 2013-07-02 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
NO339146B1 (no) * | 2005-01-19 | 2016-11-14 | Rigel Pharmaceuticals Inc | Prodrugs av 2,4-pyrimidindiaminforbindelser og deres anvendelser |
US8785437B2 (en) | 2005-01-19 | 2014-07-22 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US9266912B2 (en) | 2005-01-19 | 2016-02-23 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
US8604021B2 (en) | 2005-01-25 | 2013-12-10 | Oren Becker | Substituted arylamine compounds and methods of treatment |
EP1883302A2 (en) * | 2005-05-03 | 2008-02-06 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
EP1883302A4 (en) * | 2005-05-03 | 2009-05-20 | Rigel Pharmaceuticals Inc | JAK KINASE HEMMER AND ITS USE |
US8415365B2 (en) | 2005-06-08 | 2013-04-09 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8399472B2 (en) | 2005-06-08 | 2013-03-19 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9732073B2 (en) | 2005-06-08 | 2017-08-15 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US11198689B2 (en) | 2005-06-08 | 2021-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US10421752B2 (en) | 2005-06-08 | 2019-09-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9248190B2 (en) | 2005-06-08 | 2016-02-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US7491732B2 (en) | 2005-06-08 | 2009-02-17 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US11827628B2 (en) | 2005-06-08 | 2023-11-28 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9593082B2 (en) | 2005-06-08 | 2017-03-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2006135915A2 (en) | 2005-06-13 | 2006-12-21 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
EP1896134A2 (en) * | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
US7576053B2 (en) | 2005-06-13 | 2009-08-18 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
JP2008543855A (ja) * | 2005-06-13 | 2008-12-04 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 変形性骨疾患を処置するための方法および組成物 |
EP1890703B1 (en) * | 2005-06-14 | 2016-05-11 | Taigen Biotechnology | Pyrimidine compounds as chemokine receptors inhibitors |
EP1890703A2 (en) * | 2005-06-14 | 2008-02-27 | Taigen Biotechnology | Pyrimidine compounds |
AU2006264958B2 (en) * | 2005-07-01 | 2012-05-03 | Boehringer Ingelheim International Gmbh | 2,4-diamino-pyrimidines used as aurora inhibitors |
WO2007028445A1 (en) * | 2005-07-15 | 2007-03-15 | Glaxo Group Limited | 6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives |
WO2007009681A1 (en) * | 2005-07-15 | 2007-01-25 | Glaxo Group Limited | 1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES |
US8138199B2 (en) | 2005-11-01 | 2012-03-20 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
US7713987B2 (en) | 2005-12-06 | 2010-05-11 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2,4-diamines and their uses |
WO2007085540A1 (en) * | 2006-01-27 | 2007-08-02 | Glaxo Group Limited | 1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives |
JP4653842B2 (ja) * | 2006-02-17 | 2011-03-16 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 自己免疫疾患を治療または予防するための2,4−ピリミジンジアミン化合物 |
JP2009527496A (ja) * | 2006-02-17 | 2009-07-30 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 自己免疫疾患を治療または予防するための2,4−ピリミジンジアミン化合物 |
US8314093B2 (en) | 2006-02-17 | 2012-11-20 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
WO2007120980A2 (en) | 2006-02-17 | 2007-10-25 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
US7659280B2 (en) | 2006-02-17 | 2010-02-09 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases |
WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US11667611B2 (en) | 2006-02-24 | 2023-06-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2007132010A1 (de) * | 2006-05-15 | 2007-11-22 | Boehringer Ingelheim International Gmbh | 2, 4 -diamino pyrimidine als inhibitoren von zellzykluskinasen |
EP2357181A1 (de) * | 2006-05-15 | 2011-08-17 | Boehringer Ingelheim International GmbH | 2,4-Diaminopyrimidine als Inhibitoren von Zellzykluskinasen |
US8623887B2 (en) | 2006-05-15 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Compounds |
WO2008049123A2 (en) | 2006-10-19 | 2008-04-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases |
US8148391B2 (en) | 2006-10-23 | 2012-04-03 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors |
US8552186B2 (en) | 2006-10-23 | 2013-10-08 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors |
EP2420505A1 (en) | 2006-11-21 | 2012-02-22 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses |
WO2008064274A1 (en) | 2006-11-21 | 2008-05-29 | Rigel Pharmaceuticals, Inc. | Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
WO2008118823A3 (en) * | 2007-03-26 | 2009-05-14 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the jak pathway |
US8299087B2 (en) | 2007-03-26 | 2012-10-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
WO2008118823A2 (en) * | 2007-03-26 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
EP2154967A1 (en) * | 2007-04-16 | 2010-02-24 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
US8901143B2 (en) | 2007-04-16 | 2014-12-02 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
EP2154967A4 (en) * | 2007-04-16 | 2010-05-19 | Hutchison Medipharma Entpr Ltd | PYRIMIDINE DERIVATIVES |
US8349859B2 (en) | 2007-04-16 | 2013-01-08 | Hutchison Medipharma Enterprises Limited | Pyrimidine derivatives |
US7928109B2 (en) | 2007-04-18 | 2011-04-19 | Pfizer Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US10450297B2 (en) | 2007-04-18 | 2019-10-22 | Pfizer, Inc. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US8440822B2 (en) | 2007-04-18 | 2013-05-14 | Michael Joseph Luzzio | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US8247411B2 (en) | 2007-04-18 | 2012-08-21 | Pfizer Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
US8993585B2 (en) | 2007-07-17 | 2015-03-31 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
WO2009029682A1 (en) * | 2007-08-28 | 2009-03-05 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
WO2009080638A2 (en) | 2007-12-20 | 2009-07-02 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
WO2009080638A3 (en) * | 2007-12-20 | 2009-10-01 | Cellzome Limited | Sulfamides as zap-70 inhibitors |
EP2562163A1 (en) | 2008-01-22 | 2013-02-27 | Dow AgroSciences LLC | 5-fluoro pyrimidine derivatives as fungicides |
EP2562165A1 (en) | 2008-01-22 | 2013-02-27 | Dow AgroSciences LLC | 5-fluoro pyrimidine derivatives as fungicides |
EP2562167A1 (en) | 2008-01-22 | 2013-02-27 | Dow AgroSciences LLC | 5-fluoro pyrimidine derivatives as fungicides |
EP2562175A1 (en) | 2008-01-22 | 2013-02-27 | Dow AgroSciences LLC | 5-fluoro pyrimidine derivatives as fungicides |
EP2562166A1 (en) | 2008-01-22 | 2013-02-27 | Dow AgroSciences LLC | 5-fluoro pyrimidine derivatives as fungicides |
EP2562164A1 (en) | 2008-01-22 | 2013-02-27 | Dow AgroSciences LLC | 5-fluoro pyrimidine derivatives as fungicides |
EP2562161A1 (en) | 2008-01-22 | 2013-02-27 | Dow AgroSciences LLC | 5-fluoro pyrimidine derivatives as fungicides |
US8735418B2 (en) | 2008-02-15 | 2014-05-27 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
US8309566B2 (en) | 2008-02-15 | 2012-11-13 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
US9624229B2 (en) | 2008-02-15 | 2017-04-18 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases |
WO2009112490A1 (en) * | 2008-03-11 | 2009-09-17 | Cellzome Limited | Sulfonamides as zap-70 inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US9579320B2 (en) | 2008-04-16 | 2017-02-28 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US9868729B2 (en) | 2008-04-16 | 2018-01-16 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8349860B2 (en) | 2008-04-16 | 2013-01-08 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US8952027B2 (en) | 2008-04-16 | 2015-02-10 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
EA019973B1 (ru) * | 2008-04-16 | 2014-07-30 | Портола Фармасьютиклз, Инк. | ИНГИБИТОРЫ Syk ПРОТЕИНКИНАЗ |
US8501944B2 (en) | 2008-04-16 | 2013-08-06 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2009136995A2 (en) | 2008-04-16 | 2009-11-12 | Portola Pharmaceuticals, Inc. | Inhibitors of syk protein kinase |
US11414410B2 (en) | 2008-04-16 | 2022-08-16 | Alexion Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8937070B2 (en) | 2008-04-16 | 2015-01-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
WO2009136995A3 (en) * | 2008-04-16 | 2009-12-30 | Portola Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors |
US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
US10533001B2 (en) | 2008-04-16 | 2020-01-14 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8318755B2 (en) | 2008-04-16 | 2012-11-27 | Portola Pharmaceuticals, Inc. | Inhibitors of SYK and JAK protein kinases |
US9139581B2 (en) | 2008-04-22 | 2015-09-22 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8212033B2 (en) | 2008-05-09 | 2012-07-03 | Hutchison Medipharma Enterprises Limited | Use of substituted quinazoline compounds in treating angiogenesis-related diseases |
US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
US8497372B2 (en) | 2008-05-09 | 2013-07-30 | Hutchison Medipharma Enterprises Limited | Use of substituted quinazoline compounds in treating age-related macular degeneration |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US9012462B2 (en) | 2008-05-21 | 2015-04-21 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
US9212181B2 (en) | 2008-06-27 | 2015-12-15 | Celgene Avilomics Research, Inc. | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US8609679B2 (en) | 2008-06-27 | 2013-12-17 | Celgene Avilomics Research, Inc. | 2,4-diaminopyrimidines useful as kinase inhibitors |
US8710222B2 (en) | 2008-06-27 | 2014-04-29 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US9296737B2 (en) | 2008-06-27 | 2016-03-29 | Celgene Avilomics Research, Inc. | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US8450335B2 (en) | 2008-06-27 | 2013-05-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US10596172B2 (en) | 2008-06-27 | 2020-03-24 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US10010548B2 (en) | 2008-06-27 | 2018-07-03 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US10828300B2 (en) | 2008-06-27 | 2020-11-10 | Celgene Car Llc | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US9987276B2 (en) | 2008-06-27 | 2018-06-05 | Celgene Car Llc | Substituted 2,4-diaminopyrimidines as kinase inhibitors |
US9409921B2 (en) | 2008-06-27 | 2016-08-09 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8426430B2 (en) | 2008-06-30 | 2013-04-23 | Hutchison Medipharma Enterprises Limited | Quinazoline derivatives |
US7737157B2 (en) | 2008-08-29 | 2010-06-15 | Hutchison Medipharma Enterprises Limited | Pyrimidine compounds |
EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
JP2012503604A (ja) * | 2008-09-23 | 2012-02-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 三環式カルバメートjak阻害剤 |
US9040527B2 (en) | 2008-12-30 | 2015-05-26 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine kinase inhibitors |
US8518937B2 (en) | 2008-12-30 | 2013-08-27 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine kinase inhibitors |
WO2010078369A3 (en) * | 2008-12-30 | 2010-10-14 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine kinase inhibitors |
WO2010078369A2 (en) | 2008-12-30 | 2010-07-08 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine kinase inhibitors |
US8278299B2 (en) | 2008-12-30 | 2012-10-02 | Rigel Pharmaceuticals, Inc. | Pyrimidinediamine kinase inhibitors |
WO2010090875A1 (en) | 2009-01-21 | 2010-08-12 | Rigel Pharmaceuticals, Inc. | Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
EP2565193A1 (en) | 2009-01-23 | 2013-03-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8507675B2 (en) | 2009-01-23 | 2013-08-13 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8324200B2 (en) | 2009-01-23 | 2012-12-04 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9084795B2 (en) | 2009-01-23 | 2015-07-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9248132B2 (en) | 2009-01-23 | 2016-02-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9566283B2 (en) | 2009-01-23 | 2017-02-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US10556891B2 (en) | 2009-01-23 | 2020-02-11 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US10005767B2 (en) | 2009-01-23 | 2018-06-26 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8563569B2 (en) | 2009-01-23 | 2013-10-22 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8524901B2 (en) | 2009-01-23 | 2013-09-03 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8530656B2 (en) | 2009-01-23 | 2013-09-10 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8735400B2 (en) | 2009-01-23 | 2014-05-27 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US8563716B2 (en) | 2009-01-23 | 2013-10-22 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
US8367689B2 (en) | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
US8853230B2 (en) | 2009-05-06 | 2014-10-07 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
WO2010142766A3 (en) * | 2009-06-10 | 2011-04-14 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
WO2011002999A1 (en) | 2009-07-02 | 2011-01-06 | Rigel Pharmaceuticals, Inc. | Synthesis of n4- (2, 2-dimethyl-4- [ (dihydrogen phosphonoxy ] -3-oxo-5-pyrido [1, 4] oxazin-6-yl)-5-fluoro-n2- (3, 4, 5,-trimethoxyphenyl) -2, 4- pyrimidinediamine disodium salt |
WO2011009075A2 (en) | 2009-07-17 | 2011-01-20 | Rigel Pharmaceuticals, Inc. | Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
WO2011017178A1 (en) | 2009-07-28 | 2011-02-10 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
WO2011063241A1 (en) | 2009-11-20 | 2011-05-26 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
US9732070B2 (en) | 2009-12-01 | 2017-08-15 | Rigel Pharmaceuticals, Inc. | Protein kinase C inhibitors and uses thereof |
WO2011068898A1 (en) | 2009-12-01 | 2011-06-09 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
US8618095B2 (en) | 2010-04-13 | 2013-12-31 | Rigel Pharmaceuticals, Inc. | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
WO2011130390A1 (en) | 2010-04-13 | 2011-10-20 | Rigel Pharmaceuticals, Inc. | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
WO2012012619A1 (en) | 2010-07-21 | 2012-01-26 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
US9181222B2 (en) | 2010-07-21 | 2015-11-10 | Rigel Pharmaceuticals, Inc. | Protein kinase C inhibitors and uses thereof |
WO2012015972A1 (en) | 2010-07-28 | 2012-02-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US9604936B2 (en) | 2010-08-10 | 2017-03-28 | Celgene Car Llc | Besylate salt of a BTK inhibitor |
US8563568B2 (en) | 2010-08-10 | 2013-10-22 | Celgene Avilomics Research, Inc. | Besylate salt of a BTK inhibitor |
EP3176154A1 (en) | 2010-11-01 | 2017-06-07 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
WO2012061428A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
US8975249B2 (en) | 2010-11-01 | 2015-03-10 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
US9238629B2 (en) | 2010-11-01 | 2016-01-19 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9765038B2 (en) | 2010-11-01 | 2017-09-19 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
US10434101B2 (en) | 2010-11-01 | 2019-10-08 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
US10081606B2 (en) | 2010-11-01 | 2018-09-25 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
US11096942B2 (en) | 2010-11-01 | 2021-08-24 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
WO2012061418A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as syk modulators |
US9375431B2 (en) | 2010-11-01 | 2016-06-28 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
US9867824B2 (en) | 2010-11-01 | 2018-01-16 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
US10391094B2 (en) | 2010-11-07 | 2019-08-27 | Impact Biomedicines, Inc. | Compositions and methods for treating myelofibrosis |
US9409887B2 (en) | 2010-11-10 | 2016-08-09 | Celgene Avilomics Research, Inc. | Mutant-selective EGFR inhibitors and uses thereof |
US9868723B2 (en) | 2010-11-10 | 2018-01-16 | Celgene Car Llc | Mutant-selective EGFR inhibitors and uses thereof |
US8796255B2 (en) | 2010-11-10 | 2014-08-05 | Celgene Avilomics Research, Inc | Mutant-selective EGFR inhibitors and uses thereof |
US10213427B2 (en) | 2010-12-22 | 2019-02-26 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US10813930B2 (en) | 2010-12-22 | 2020-10-27 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US9533954B2 (en) | 2010-12-22 | 2017-01-03 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
US10266500B2 (en) | 2011-04-22 | 2019-04-23 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
US9701643B2 (en) | 2011-04-22 | 2017-07-11 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
US10040770B2 (en) | 2011-04-22 | 2018-08-07 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
US11325890B2 (en) | 2011-04-22 | 2022-05-10 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
US10919865B2 (en) | 2011-04-22 | 2021-02-16 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
US9139534B2 (en) | 2011-04-22 | 2015-09-22 | Signal Pharmaceuticals, Llc | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
US8877760B2 (en) | 2011-11-23 | 2014-11-04 | Portola Pharmaceuticals, Inc. | Substituted pyrazine-2-carboxamide kinase inhibitors |
US9359308B2 (en) | 2011-11-23 | 2016-06-07 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
WO2013078466A1 (en) | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
US10004741B2 (en) | 2012-03-15 | 2018-06-26 | Celgene Car Llc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US10570099B2 (en) | 2012-03-15 | 2020-02-25 | Celgene Car Llc | Salts of an epidermal growth factor receptor kinase inhibitor |
US9539255B2 (en) | 2012-03-15 | 2017-01-10 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US9540335B2 (en) | 2012-03-15 | 2017-01-10 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
US9056839B2 (en) | 2012-03-15 | 2015-06-16 | Celgene Avilomics Research, Inc. | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US9108927B2 (en) | 2012-03-15 | 2015-08-18 | Celgene Avilomics Research, Inc. | Salts of an epidermal growth factor receptor kinase inhibitor |
US11292772B2 (en) | 2012-03-15 | 2022-04-05 | Celgene Car Llc | Salts of an epidermal growth factor receptor kinase inhibitor |
US10946016B2 (en) | 2012-03-15 | 2021-03-16 | Celgene Car Llc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
US10005738B2 (en) | 2012-03-15 | 2018-06-26 | Celgene Car Llc | Salts of an epidermal growth factor receptor kinase inhibitor |
US9834571B2 (en) | 2012-05-05 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
US11840534B2 (en) | 2012-06-13 | 2023-12-12 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US10131667B2 (en) | 2012-06-13 | 2018-11-20 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US11053246B2 (en) | 2012-06-13 | 2021-07-06 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9745311B2 (en) | 2012-08-10 | 2017-08-29 | Incyte Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
US9913843B2 (en) | 2012-12-04 | 2018-03-13 | Rigel Pharmaceuticals, Inc. | Protein kinase C inhibitors and uses thereof |
WO2014089112A1 (en) | 2012-12-04 | 2014-06-12 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
US9062068B2 (en) | 2012-12-04 | 2015-06-23 | Rigel Pharmaceuticals, Inc. | Protein kinase C inhibitors and uses thereof |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9549927B2 (en) | 2012-12-21 | 2017-01-24 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
WO2014116973A1 (en) | 2013-01-25 | 2014-07-31 | Rigel Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory bowel diseases |
US9504686B2 (en) | 2013-02-08 | 2016-11-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9796700B2 (en) | 2013-02-08 | 2017-10-24 | Celgene Car Llc | ERK inhibitors and uses thereof |
US9980964B2 (en) | 2013-02-08 | 2018-05-29 | Celgene Car Llc | ERK inhibitors and uses thereof |
US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
WO2014151900A1 (en) | 2013-03-14 | 2014-09-25 | Rigel Pharmaceuticals, Inc. | Protein kinase c inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US10947230B2 (en) | 2013-04-19 | 2021-03-16 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11530214B2 (en) | 2013-04-19 | 2022-12-20 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US10450313B2 (en) | 2013-04-19 | 2019-10-22 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US10040790B2 (en) | 2013-04-19 | 2018-08-07 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US9533984B2 (en) | 2013-04-19 | 2017-01-03 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US11241430B2 (en) | 2014-01-30 | 2022-02-08 | Signal Pharmaceuticals, Llc | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
US10226461B2 (en) | 2014-01-30 | 2019-03-12 | Signal Pharmaceuticals, Llc | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
US9814713B2 (en) | 2014-01-30 | 2017-11-14 | Signal Pharmaceuticals, Llc | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
US10517873B2 (en) | 2014-01-30 | 2019-12-31 | Signal Pharmaceuticals, Llc | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
US9365524B2 (en) | 2014-01-30 | 2016-06-14 | Signal Pharmaceuticals, Llc | Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
US10202364B2 (en) | 2014-08-13 | 2019-02-12 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10197579B2 (en) | 2014-12-16 | 2019-02-05 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-Jun N-terminal kinase in skin |
US9513297B2 (en) | 2014-12-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-Jun N-terminal kinase in skin |
US10131639B2 (en) | 2014-12-16 | 2018-11-20 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4methylcyclohexylamino)-pyrimidine-5-carboxamide |
US9796685B2 (en) | 2014-12-16 | 2017-10-24 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10590089B2 (en) | 2014-12-16 | 2020-03-17 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10689351B2 (en) | 2015-01-29 | 2020-06-23 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10975039B2 (en) | 2015-01-29 | 2021-04-13 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US11492332B2 (en) | 2015-01-29 | 2022-11-08 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
US10251892B2 (en) | 2015-02-20 | 2019-04-09 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11173162B2 (en) | 2015-02-20 | 2021-11-16 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9890156B2 (en) | 2015-02-20 | 2018-02-13 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9801889B2 (en) | 2015-02-20 | 2017-10-31 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10016438B2 (en) | 2015-02-20 | 2018-07-10 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11014923B2 (en) | 2015-02-20 | 2021-05-25 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9708318B2 (en) | 2015-02-20 | 2017-07-18 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11667635B2 (en) | 2015-02-20 | 2023-06-06 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10632126B2 (en) | 2015-02-20 | 2020-04-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10738048B2 (en) | 2015-02-20 | 2020-08-11 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US10214528B2 (en) | 2015-02-20 | 2019-02-26 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11192847B2 (en) | 2015-07-24 | 2021-12-07 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
US10252981B2 (en) | 2015-07-24 | 2019-04-09 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
US10774033B2 (en) | 2015-07-24 | 2020-09-15 | Celgene Corporation | Methods of synthesis of (1R, 2R, 5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
US11780801B2 (en) | 2015-07-24 | 2023-10-10 | Celgene Corporation | Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein |
US11649242B2 (en) | 2017-03-20 | 2023-05-16 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
US11396513B2 (en) | 2017-03-20 | 2022-07-26 | Forma Therapeutics, Inc. | Compositions for activating pyruvate kinase |
US11014927B2 (en) | 2017-03-20 | 2021-05-25 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators |
US10611762B2 (en) | 2017-05-26 | 2020-04-07 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US11472801B2 (en) | 2017-05-26 | 2022-10-18 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US20230030115A1 (en) * | 2017-06-30 | 2023-02-02 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11071725B2 (en) | 2018-09-19 | 2021-07-27 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
US11980611B2 (en) | 2018-09-19 | 2024-05-14 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
US11844787B2 (en) | 2018-09-19 | 2023-12-19 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
US11001588B2 (en) | 2018-09-19 | 2021-05-11 | Forma Therapeutics, Inc. | Activating pyruvate kinase R and mutants thereof |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
WO2020243612A1 (en) | 2019-05-29 | 2020-12-03 | Rigel Pharmaceuticals, Inc. | Method of preventing and treating thrombosis |
US11529350B2 (en) | 2019-07-03 | 2022-12-20 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
WO2021026451A1 (en) | 2019-08-08 | 2021-02-11 | Rigel Pharmaceuticals, Inc. | Compounds and method for treating cytokine release syndrome |
WO2021030526A1 (en) | 2019-08-14 | 2021-02-18 | Rigel Pharmaceuticals, Inc. | Method of blocking or ameliorating cytokine release syndrome |
CN110746402A (zh) * | 2019-09-21 | 2020-02-04 | 温州医科大学 | 一种2-n-芳基-4-n-芳基-5-氟嘧啶类化合物及其制备方法和应用 |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US12024517B2 (en) | 2021-10-18 | 2024-07-02 | Incyte Corporation | Salts of an FGFR inhibitor |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1534286B1 (en) | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | |
US10259826B2 (en) | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | |
EP1814878B1 (en) | Spiro-2, 4-pyrimidinediamine compounds and their uses | |
US7435814B2 (en) | 2,4-Pyrimidinediamine compounds and their uses | |
EP1984357A2 (en) | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases | |
RU2376992C2 (ru) | Способы лечения или профилактики аутоиммунных заболеваний с помощью соединений 2,4-пиримидиндиамина | |
EP2316459A1 (en) | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | |
KR101297924B1 (ko) | 2,4-피리미딘디아민 화합물을 이용한 자가면역질환의 치료및 예방 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-2005/0069 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003784871 Country of ref document: EP Ref document number: 166241 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2492325 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537752 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/00775 Country of ref document: ZA Ref document number: P20050089A Country of ref document: HR Ref document number: 200500775 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/001096 Country of ref document: MX Ref document number: 05002035 Country of ref document: SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 373455 Country of ref document: PL Ref document number: 2005506142 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057001685 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003265336 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005105344 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 302/KOLNP/2005 Country of ref document: IN Ref document number: 1200500245 Country of ref document: VN Ref document number: A20050080 Country of ref document: BY |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038211203 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 05002035 Country of ref document: SE |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057001685 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003784871 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 214607 Country of ref document: IL |